<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oxcarbazepine add‐on for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library</title> <meta content="Oxcarbazepine add‐on for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012433.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oxcarbazepine add‐on for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012433.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012433.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oxcarbazepine add‐on for drug‐resistant focal epilepsy" name="citation_title"/> <meta content="Rebecca Bresnahan" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="rebecca.bresnahan@liverpool.ac.uk" name="citation_author_email"/> <meta content="Margaret Atim‐Oluk" name="citation_author"/> <meta content="South Wales Deanery" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012433.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012433.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012433.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012433.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [*therapeutic use]; Drug Resistant Epilepsy [*drug therapy]; Drug Therapy, Combination; Intention to Treat Analysis; Oxcarbazepine [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012433.pub2&amp;doi=10.1002/14651858.CD012433.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="6nHUP32m";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012433\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012433\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","fa","fr","es","ru","pl","ms","ja","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012433.pub2",title:"Oxcarbazepine add\\u2010on for drug\\u2010resistant focal epilepsy",firstPublishedDate:"Mar 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012433.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012433.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012433.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012433.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012433.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012433.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012433.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012433.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012433.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012433.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3536 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012433.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0097"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/appendices#CD012433-sec-0102"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/table_n/CD012433StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/table_n/CD012433StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oxcarbazepine add‐on for drug‐resistant focal epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#CD012433-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bresnahan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#CD012433-cr-0003">Margaret Atim‐Oluk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information#CD012433-cr-0004">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information/en#CD012433-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012433.pub2">https://doi.org/10.1002/14651858.CD012433.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012433-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012433-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012433-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012433-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012433-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012433-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012433-abs-0001" lang="en"> <section id="CD012433-sec-0001"> <h3 class="title" id="CD012433-sec-0001">Background</h3> <p>Epilepsy is a common neurological disorder. In approximately 30% of epilepsy cases, seizures are uncontrolled by one antiepileptic drug (AED). These people require treatment with a combination of multiple AEDs and are described as having drug‐resistant epilepsy. Oxcarbazepine is a keto‐analogue of carbamazepine, an established AED, and can be used as an add‐on treatment for drug‐resistant epilepsy. </p> </section> <section id="CD012433-sec-0002"> <h3 class="title" id="CD012433-sec-0002">Objectives</h3> <p>To assess the efficacy and tolerability of oxcarbazepine as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> <section id="CD012433-sec-0003"> <h3 class="title" id="CD012433-sec-0003">Search methods</h3> <p>The following databases were searched on 24 September 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); Medline (Ovid) 1946 to 21 September 2018; <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>; and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>). Originally, we also searched SCOPUS as a substitute for Embase, but this is no longer necessary, because randomised and quasi‐randomised controlled trials in Embase are now included in CENTRAL. </p> </section> <section id="CD012433-sec-0004"> <h3 class="title" id="CD012433-sec-0004">Selection criteria</h3> <p>Randomised controlled trials with parallel‐group or cross‐over design, recruiting people of any age with drug‐resistant focal epilepsy. We accepted any level of blinding and trials could be placebo‐ or active‐controlled. </p> </section> <section id="CD012433-sec-0005"> <h3 class="title" id="CD012433-sec-0005">Data collection and analysis</h3> <p>In accordance with the methodological procedures expected by the Cochrane Collaboration, two review authors independently assessed trial eligibility before extracting data and assessing risk of bias. We assessed the primary outcomes: median percentage seizure reduction per 28 days; 50% or greater reduction in seizure frequency; and adverse effects including ataxia, hyponatraemia, and somnolence. We assessed the secondary outcomes: seizure freedom; treatment withdrawal; cognitive effects; and quality of life. We used an intention‐to‐treat population for all primary analyses. We present results as risk ratios (RR) with 95% confidence intervals (CI), with the exception of adverse effects which we present with 99% CI. </p> </section> <section id="CD012433-sec-0006"> <h3 class="title" id="CD012433-sec-0006">Main results</h3> <p>We identified six eligible studies, involving 1593 participants. We judged that three studies were at unclear risk of bias and three were at high risk of bias. Bias mainly arose from lack of methodological details and from high attrition rates. Participants were aged 1 month to 65 years, with a diagnosis of drug‐resistant focal epilepsy. All studies were either placebo‐ or alternative‐dose‐controlled with parallel‐group design. The treatment period varied from 9 days to 26 weeks. </p> <p>The median percentage seizure reduction per 28 days (3 studies; moderate‐certainty evidence) ranged from 26% to 83.3% for participants randomised to experimental oxcarbazepine compared to 7.6% to 28.7% for participants randomised to control treatment. Oxcarbazepine may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to 2.56; random‐effects model; 6 studies; low‐certainty evidence). For seizure freedom, the RR was 2.86 (95% CI 1.19 to 6.87; random‐effects model; 5 studies; low‐certainty evidence), suggesting an advantageous effectiveness of oxcarbazepine over control treatment. Treatment with oxcarbazepine was associated with an increased treatment withdrawal rate compared to control (RR 1.75, 95% CI 1.44 to 2.13; fixed‐effect model; 6 studies; moderate‐certainty evidence). The largest oxcarbazepine dose used, 2400 mg/d, was associated with a higher treatment withdrawal rate (RR 2.38, 95% CI 1.92 to 2.94; fixed‐effect model; 2 studies) compared to control, than 1200 mg/d (RR 1.54, 95% CI 1.21 to 1.95; fixed‐effect model; 3 studies) or 600 mg/d oxcarbazepine (RR 0.79, 95% CI 0.55 to 1.15; fixed‐effect model; 1 study). Treatment with oxcarbazepine was associated with an increased incidence of multiple adverse effects including: ataxia (RR 2.54, 99% CI 0.86 to 7.54; random‐effects model; 5 studies; moderate‐certainty evidence); and somnolence (RR 2.03, 99% CI 1.17 to 3.54; random‐effects model; 6 studies; low‐certainty evidence). Hyponatraemia occurred more frequently with oxcarbazepine treatment but not significantly so (RR 2.53, 99% CI 0.27 to 23.85; fixed‐effect model; 6 studies; moderate‐certainty evidence). </p> </section> <section id="CD012433-sec-0007"> <h3 class="title" id="CD012433-sec-0007">Authors' conclusions</h3> <p>Oxcarbazepine might be effective at reducing seizure frequency when used as an add‐on for drug‐resistant focal epilepsy. The efficacy outcomes — 50% or greater seizure reduction and seizure freedom — were derived from low‐certainty evidence. We are, therefore, uncertain whether the estimated effect size is representative of the true effect. In contrast, the evidence for median percentage seizure reduction and treatment withdrawal were of moderate certainty: thus, we are fairly certain of the effect estimates' reliability. Overall, we are unsure of the true efficacy of oxcarbazepine, but have concerns about its tolerability. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012433-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012433-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012433-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012433-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012433-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012433-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012433-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012433-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012433-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012433-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012433-abs-0004" lang="en"> <h3>Oxcarbazepine add‐on for drug‐resistant focal epilepsy</h3> <p><b>Background</b> </p> <p>Epilepsy is a neurological disorder which causes people to have seizures. Most people can control their epilepsy with a single antiepileptic drug. Some people, however, require multiple antiepileptic drugs to control their epilepsy, and are said to have drug‐resistant epilepsy. Oxcarbazepine is an antiepileptic drug and is similar to an older antiepileptic drug, carbamazepine. Oxcarbazepine can be taken as an add‐on treatment, alongside other antiepileptic medication, to treat drug‐resistant epilepsy. </p> <p><b>Aim of the review</b> </p> <p>This review examined whether oxcarbazepine is tolerable and effective when used alongside other antiepileptic medication by people with drug‐resistant focal epilepsy (epilepsy that originates from one area of the brain). </p> <p><b>Results</b> </p> <p>We included six clinical trials that investigated oxcarbazepine as an add‐on treatment for people with drug‐resistant focal epilepsy. There were 1593 people across the studies and they were aged from 1 month to 65 years. </p> <p>People who received oxcarbazepine in addition to their normal antiepileptic medication were more likely to have a 50% or greater reduction in the frequency of their seizures compared to people who were on a control treatment, which is believed to have little or no effect. They were also nearly three times more likely to be free from all seizures than those receiving control treatment. Both of these findings suggest that oxcarbazepine is effective at treating drug‐resistant focal epilepsy. These findings are, however, based on evidence that was of low certainty. This means that we are not confident that the findings that we have reported are accurate. </p> <p>People who received oxcarbazepine add‐on treatment were also more likely to withdraw from the studies and were more likely to experience side effects, including dizziness and drowsiness, than people receiving control add‐on treatment. The evidence for treatment withdrawal was of moderate certainty, and this means that we can be fairly confident that this is a true effect. </p> <p><b>Authors' conclusions</b> </p> <p>As a result of the low‐certainty evidence, we cannot be sure that oxcarbazepine is an effective add‐on treatment for people with drug‐resistant focal epilepsy. Instead, we have concerns about the tolerability of oxcarbazepine because of the increased number of people who withdrew from treatment and who experienced side effects. </p> <p>The evidence is current to September 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012433-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012433-sec-0097"></div> <h3 class="title" id="CD012433-sec-0098">Implications for practice</h3> <section id="CD012433-sec-0098"> <p>This review provides limited information about the efficacy and tolerability of oxcarbazepine as an add‐on therapy for people with drug‐resistant focal epilepsy. Although the evidence presented here did demonstrate that oxcarbazepine effectively reduces seizure frequency, the evidence for this outcome was of low certainty. Consequently, we cannot be certain that this finding is accurate. By contrast, with regards to tolerability the evidence for treatment withdrawal was of moderate certainty, and thus should be a fairly accurate estimate of the true effect of oxcarbazepine. This review revealed an increased treatment withdrawal rate for participants who receive oxcarbazepine compared to those who receive control. Moreover, people receiving oxcarbazepine were shown to be more at risk of experiencing several different adverse effects. </p> <p>We suspect that there are issues with the tolerability of oxcarbazepine that are especially prevalent at the higher doses of oxcarbazepine. We observed higher treatment withdrawal rates with increased oxcarbazepine dose. Of further importance, as we have highlighted in <a href="#CD012433-sec-0081">Incomplete outcome data (attrition bias)</a> subsection, tolerability could be underestimated for the highest dose of oxcarbazepine (2400 mg/d), due to the down‐titration of approximately a quarter of randomised participants from 2400 mg/d to 1800 mg/d. Consequently, we are unable to provide a reliable interpretation of the tolerability of oxcarbazepine at the highest dose but infer that there are serious issues with tolerability at 2400 mg/d oxcarbazepine. </p> </section> <h3 class="title" id="CD012433-sec-0099">Implications for research</h3> <section id="CD012433-sec-0099"> <p>Additional studies are necessary to correctly inform clinical practice. Specifically, we require more clinical trials which investigate multiple doses of oxcarbazepine to be conducted and which vary in treatment duration and type of control group. The data from these trials could then be incorporated into an updated review in order to adequately power the subgroup analyses presented here. Additional studies incorporating multiple doses are especially important to resolve whether the concerns regarding tolerability are notable with all doses of oxcarbazepine or are solely a feature of the higher doses of oxcarbazepine. Longer‐term trials are also desirable as they are able to assess the long‐term tolerability of drugs, and can further establish whether drug tolerance develops. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012433-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012433-sec-0029"></div> <div class="table" id="CD012433-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine compared to control for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxcarbazepine compared to control for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> drug‐resistant focal epilepsy<br/> <b>Setting:</b> outpatients (except for 1 study which was conducted in a hospital setting to allow EEG‐recording)<br/> <b>Intervention:</b> Oxcarbazepine (600 mg/d, 1200 mg/d, 2400 mg/d, 10 mg/kg/d, and 60 mg/kg/d)<br/> <b>Comparison:</b> control (placebo or alternative lower dose of oxcarbazepine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI for efficacy outcomes and 99% CI for adverse effects)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Oxcarbazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median percentage seizure reduction per 28 days</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The values reported ranged from 7.6% to 28.7% seizure reduction with 2 of the 3 studies specifically reporting percentage reductions of less than 10%. The median percentage seizure reduction for participants randomised to experimental oxcarbazepine treatment ranged from 26% to 83.3%. Importantly, for each study that described this outcome, the median percentage seizure reduction reported was consistently higher in experimental oxcarbazepine treatment group than in the control group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1494</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxcarbazepine likely increases the median percentage seizure reduction per 28 days attained by participants. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% or greater reduction in seizure frequency</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.80</b><br/> (1.27 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the number of participants achieving a 50% or greater reduction in seizure frequency but we are uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (275 to 555) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ataxia</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.54</b><br/> (0.86 to 7.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1227</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases the incidence of ataxia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (43 to 380) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hyponatraemia</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>#</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.53</b><br/> (0.27 to 23.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases the incidence of hyponatraemia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 558</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1035</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.03</b><br/> (1.17 to 3.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the incidence of somnolence but we are uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000<br/> (140 to 425) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Seizure freedom</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.86</b><br/> (1.19 to 6.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1494</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the incidence of seizure freedom amongst participants but we are uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/> (42 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.75</b><br/> (1.44 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases treatment withdrawal.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>292 per 1000<br/> (240 to 355) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects). </p> <p><sup>#</sup> For the adverse event, <b>Hyponatraemia</b> , we have reported the <b>Number of events recorded per number of randomised participants</b> rather than the <b>Anticipated absolute effects</b> . Under the circumstances, this measure was considered more informative.<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded once for risk of bias: 3 of the studies had unclear risk of bias and 3 studies had high risk of bias. This was largely due to studies not specifying their methods for randomisation and allocation concealment, as well as due to high attrition rates noted in some studies. </p> <p><sup>b</sup> Evidence downgraded once due to inconsistency: significant heterogeneity between studies detected. </p> <p><sup>c</sup>Evidence downgraded once due to imprecision: wide confidence intervals and sub‐optimal number of events included in analysis. </p> <p><sup>d</sup>Evidence upgraded once for large effect: large effect size (RR &gt; 2.00). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012433-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012433-sec-0030"></div> <section id="CD012433-sec-0031"> <h3 class="title" id="CD012433-sec-0031">Description of the condition</h3> <p>Epilepsy is a disease arising from an enduring and pathological excessive discharge of a set of neurons in the brain, clinically characterised by recurrent unprovoked epileptic seizures or in the context of an epilepsy syndrome. There are many causes alongside several clinical and electroencephalographic manifestations that can result in epilepsy (<a href="./references#CD012433-bbs2-0030" title="FisherRS , AcevedoC , ArzimanoglouA , BogaczA , CrossJH , ElgerCE , et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia2014;55(4):475‐82. ">Fisher 2014</a>). The condition is associated with considerable physical, cognitive, psychiatric and psychological co‐morbidity (<a href="./references#CD012433-bbs2-0044" title="LaFranceWCJr , KannerAM , HermannB . Chapter 20: psychiatric comorbidities in epilepsy. International Review of Neurobiology2008;83:347‐83. ">LaFrance 2008</a>; <a href="./references#CD012433-bbs2-0027" title="BurtonK , RothgatheJ , WhittakerRG , MankadK , HunterE , BurtonMJ , et al. Co‐morbidity of epilepsy in Tanzanian children: a community‐based case‐control study. Seizure2012;21(3):169‐74. ">Burton 2012</a>). </p> <p>Epilepsy is common worldwide. A meta‐analysis of 65 studies estimated lifetime prevalence in high‐income countries as 5.8 per 1000; whereas in resource‐poor countries the estimate was 10.3 per 1000 in urban areas, and in rural areas the estimate was 15.4 per 1000 (<a href="./references#CD012433-bbs2-0025" title="BellGS , NeliganA , SanderJW . An unknown quantity ‐ the worldwide prevalence of epilepsy. Epilepsia2014;55(7):958‐62. ">Bell 2014</a>). </p> <p>The United Kingdom General Practice Study of Epilepsy found 60% of epilepsies to be convulsive, of which around two‐thirds comprised focal seizures or focal seizures with secondary generalisation (<a href="./references#CD012433-bbs2-0052" title="SanderJW , HartYM , JohnsonAL , ShorvonSD . National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet1990;336(8726):1267‐71. ">Sander 1990</a>; <a href="./references#CD012433-bbs2-0055" title="ShorvonS . Handbook of Epilepsy Treatment. 2nd Edition. Oxford: Blackwell Science, 2013. ">Shorvon 2014</a>). Epilepsy is commonly treated with antiepileptic drugs (AEDs), with many patients rendered seizure‐free. Unfortunately, an estimated 30% of epilepsy cases are resistant to conventional AED regimens and can require several agents to control seizures (<a href="./references#CD012433-bbs2-0029" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>; <a href="./references#CD012433-bbs2-0043" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342(5):314‐9. ">Kwan 2000</a>). This is especially prevalent with focal seizures which originate from one area of the brain. Drug‐resistant epilepsy is defined as "failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom" (<a href="./references#CD012433-bbs2-0038" title="KwanP , ArzimanoglouA , BergAT , BrodieMJ , HauserWA , MathernG , et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia2009;51(6):1069‐77. ">ILAE 2009</a>). There are also non‐medical interventions available for epilepsy, such as vagal nerve stimulation or surgery (<a href="./references#CD012433-bbs2-0047" title="PanebiancoM , RigbyA , WestonJ , MarsonAG . Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD002896.pub2] ">Panebianco 2015</a>; <a href="./references#CD012433-bbs2-0058" title="WestS , Nolan , S , CottonJ , CandhiS , WestonJ , SudanA , et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD010541.pub3] ">West 2019</a>). </p> </section> <section id="CD012433-sec-0032"> <h3 class="title" id="CD012433-sec-0032">Description of the intervention</h3> <p>Oxcarbazepine is an analogue of carbamazepine. Oxcarbazepine is thought to have certain advantages over carbamazepine. In particular, there are fewer side effects associated with oxcarbazepine and the dose can be titrated to a therapeutic dose more quickly (<a href="./references#CD012433-bbs2-0034" title="GrantSM , FauldsD . Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs1992;43(6):873‐8. ">Grant 1992</a>). Oxcarbazepine is an AED used as monotherapy for children and adults with focal‐onset seizures. It is established as an efficacious initial monotherapy in children and as a potentially efficacious initial monotherapy for adults (<a href="./references#CD012433-bbs2-0032" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , GuerreiroC , KälviäinenR , et al. ILAE Subcommission on AED Guidelines: updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2013;54(3):551‐63. ">Glauser 2013</a>). </p> </section> <section id="CD012433-sec-0033"> <h3 class="title" id="CD012433-sec-0033">How the intervention might work</h3> <p>AEDs have numerous modes of action. Generally, they inhibit generation of seizure discharge by communicating with several molecular targets in the brain to reduce neuronal excitation or increase inhibition (<a href="./references#CD012433-bbs2-0048" title="PorterRJ , RogawskiMA . Chapter 24 ‐ Antiseizure Drugs. In: KatzungBG , TrevorAJ editor(s). Basic and Clinical Pharmacology. 14th Edition. Ohio (OH): McGraw‐Hill Education, 2018:409. ">Porter 2018</a>). Oxcarbazepine has been shown to exert antiepileptic activity by blockade of voltage‐dependent sodium channels in the brain. Based on in vitro and in vivo findings and compared with antiepileptic drugs such as carbamazepine, phenytoin and phenobarbital, oxcarbazepine has a low propensity for drug‒drug interactions (<a href="./references#CD012433-bbs2-0031" title="FleschG . Overview of the clinical pharmacokinetics of oxcarbazepine. Clinical Drug Investigation2004;24(4):185‐203. ">Flesch 2004</a>). Oxcarbazepine is, however, metabolised hepatically and is rapidly reduced by cytosolic enzymes in the liver to its monohydroxy derivative (MHD), which is responsible for the pharmacological effect of the drug. Oxcarbazepine could, therefore, potentiate other AEDs that are metabolised hepatically. At oxcarbazepine doses above 1.2 g, a 40% increase in the concentration of phenytoin and a 15% increase in phenobarbital levels are observed. Furthermore, oxcarbazepine is associated with decreased clearance with moderate to severe renal impairment. Dose adjustments are thus necessary in situations of AED polypharmacy and in instances of moderate to severe renal impairment (<a href="./references#CD012433-bbs2-0031" title="FleschG . Overview of the clinical pharmacokinetics of oxcarbazepine. Clinical Drug Investigation2004;24(4):185‐203. ">Flesch 2004</a>). </p> </section> <section id="CD012433-sec-0034"> <h3 class="title" id="CD012433-sec-0034">Why it is important to do this review</h3> <p>A large amount of evidence has been accrued regarding the efficacy and tolerability of new AEDs. The International League Against Epilepsy and other organisations have produced guidelines on how to select new AEDs (<a href="./references#CD012433-bbs2-0056" title="SmithPEM , UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure2001;10(2):87‐91. ">UK Oxcarbazepine Advisory Board 2001</a>; <a href="./references#CD012433-bbs2-0040" title="KangHC , HuQ , LiuXY , LiuZG , ZengZ , LiuJL , et al. A follow up study on newer anti‐epileptic drugs as add‐on and monotherapy for partial epilepsy in China. Chinese Medical Journal2012;125(4):646‐51. ">Kang 2012</a>). New AEDs have been tested and used with success, mainly as add‐on therapies to standard drugs such as phenytoin, carbamazepine and valproate. The majority of trials investigating add‐on therapy with AEDs have recruited patients with focal epilepsy (experiencing simple focal and/or complex focal and/or secondary generalised tonic‐clonic seizures; <a href="./references#CD012433-bbs2-0037" title="Anonymous . Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the International League Against Epilepsy. Epilepsia1989;30(4):389‐99. ">ILAE 1989</a>) that have been resistant to antiepileptic drug treatment. </p> <p>The introduction of several new AEDs means that systematic reviews are needed to determine their effect as add‐on agents for people with focal seizures. These reviews will help inform clinicians on the best add‐on agents to use for their patients (<a href="./references#CD012433-bbs2-0046" title="MarsonAG , KadirZA , HuttonJL , ChadwickDW . The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia1997;38(8):859‐80. ">Marson 1997</a>; <a href="./references#CD012433-bbs2-0049" title="PriviteraMD . Evidence‐based medicine and antiepileptic drugs. Epilepsia1999;40(Suppl 5):S47‐S56. ">Privitera 1999</a>). We therefore present a systematic review focusing on the effects of oxcarbazepine on seizures, side effects, cognition and quality of life when used as an add‐on treatment for patients with drug‐resistant focal epilepsy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012433-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012433-sec-0035"></div> <p>To assess the efficacy and tolerability of oxcarbazepine as an add‐on treatment for people with drug‐resistant focal epilepsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012433-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012433-sec-0036"></div> <section id="CD012433-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012433-sec-0038"> <h4 class="title">Types of studies</h4> <p>To be included in the review, we required studies to meet the following criteria.</p> <p> <ol id="CD012433-list-0001"> <li> <p>Randomised controlled trials (RCTs), including quasi‐randomised trials.</p> </li> <li> <p>Double, single or unblinded trials.</p> </li> <li> <p>Placebo‐controlled or active‐controlled studies.</p> </li> <li> <p>Parallel group or cross‐over studies. For cross‐over studies, we planned to use the first treatment period as a parallel trial. </p> </li> </ol> </p> </section> <section id="CD012433-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults and children with drug‐resistant focal epilepsy, as defined by the International League Against Epilepsy (<a href="./references#CD012433-bbs2-0038" title="KwanP , ArzimanoglouA , BergAT , BrodieMJ , HauserWA , MathernG , et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia2009;51(6):1069‐77. ">ILAE 2009</a>). We included participants who had undergone other interventions to treat epilepsy, such as surgery, vagal nerve stimulation or ketogenic diet. </p> </section> <section id="CD012433-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD012433-list-0002"> <li> <p>The active treatment group received therapy with oxcarbazepine, in addition to their usual treatment. </p> </li> <li> <p>The control group received placebo, an alternative antiepileptic drug or a different dose of oxcarbazepine, in addition to their usual treatment. </p> </li> </ol> </p> </section> <section id="CD012433-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012433-sec-0042"> <h5 class="title">Primary outcomes</h5> <section id="CD012433-sec-0043"> <h6 class="title">(1) Median percentage seizure reduction per 28 days</h6> <p>The median percentage seizure reduction every four weeks in the treatment period compared to the pre‐randomisation baseline period. </p> </section> <section id="CD012433-sec-0044"> <h6 class="title">(2) 50% or greater reduction in seizure frequency</h6> <p>The proportion of participants with a 50% or greater reduction in seizure frequency in the treatment period compared to the pre‐randomisation baseline period. </p> </section> <section id="CD012433-sec-0045"> <h6 class="title">(3) Adverse effects</h6> <p>The proportion of participants who experienced any of the following adverse effects.</p> <p> <ol id="CD012433-list-0003"> <li> <p>Ataxia</p> </li> <li> <p>Dizziness</p> </li> <li> <p>Fatigue</p> </li> <li> <p>Nausea</p> </li> <li> <p>Somnolence</p> </li> <li> <p>Headache</p> </li> <li> <p>Hyponatraemia</p> </li> <li> <p>Vertigo</p> </li> <li> <p>Diplopia</p> </li> <li> <p>Rash</p> </li> <li> <p>Tremor</p> </li> <li> <p>Pyrexia</p> </li> <li> <p>Abnormal gait</p> </li> <li> <p>Abdominal pain</p> </li> <li> <p>Nystagmus</p> </li> <li> <p>Viral infection</p> </li> <li> <p>Vomiting</p> </li> <li> <p>Abnormal vision</p> </li> <li> <p>Any other adverse effect</p> </li> </ol> </p> </section> </section> <section id="CD012433-sec-0046"> <h5 class="title">Secondary outcomes</h5> <section id="CD012433-sec-0047"> <h6 class="title">(1) Seizure freedom</h6> <p>The proportion of participants who had complete cessation of seizures during the treatment period. </p> </section> <section id="CD012433-sec-0048"> <h6 class="title">(2) Treatment withdrawal</h6> <p>We chose the proportion of participants who withdrew from the treatment during the course of the treatment period as a 'global measure of tolerability'. In studies of relatively short duration, treatment is unlikely to be withdrawn due to lack of efficacy and any treatment withdrawal is likely due to side effects. </p> </section> <section id="CD012433-sec-0049"> <h6 class="title">(3) Cognitive effects</h6> <p>At present, there is no consensus as to which instruments should be used to assess the effects of AEDs on cognition. As a result, we approached the assessment of cognitive effects in a heterogeneous way (<a href="./references#CD012433-bbs2-0028" title="CochraneHC , BakerGA , ChadwickDW . Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia1998;39(10):1088‐97. ">Cochrane 1998</a>). </p> </section> <section id="CD012433-sec-0050"> <h6 class="title">(4) Quality of life</h6> <p>Once again, there is no consensus as to which instruments should be used to assess this and we expected to see significant heterogeneity in the outcome measures used. </p> </section> </section> </section> </section> <section id="CD012433-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012433-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We ran the first searches for this review in July 2014. We ran subsequent searches in December 2016; and we ran the most recent searches on 24 September 2018, when we searched the following databases. There were no language restrictions. </p> <p> <ol id="CD012433-list-0004"> <li> <p>Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), using the search strategy set out in <a href="./appendices#CD012433-sec-0103">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid) 1946 to 21 September 2018 using the search strategy set out in <a href="./appendices#CD012433-sec-0104">Appendix 2</a>. </p> </li> <li> <p><a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> using the search strategy set out in <a href="./appendices#CD012433-sec-0105">Appendix 3</a>. </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform (ICTRP)</a> using the search strategy set out in <a href="./appendices#CD012433-sec-0106">Appendix 4</a>. </p> </li> </ol> </p> <p>Previously SCOPUS was searched as an alternative to Embase but this is no longer necessary, because randomised and quasi‐randomised controlled trials in Embase are now included in CENTRAL. </p> </section> <section id="CD012433-sec-0053"> <h4 class="title">Searching other resources</h4> <section id="CD012433-sec-0054"> <h5 class="title">References from published studies</h5> <p>We reviewed the reference lists of retrieved studies to search for additional reports of relevant studies. </p> </section> <section id="CD012433-sec-0055"> <h5 class="title">Efforts to identify unpublished studies</h5> <p>We sought unpublished data from Novartis (the manufacturer of oxcarbazepine); we were unable to obtain any, however. </p> </section> <section id="CD012433-sec-0056"> <h5 class="title">Other</h5> <p>We asked colleagues if they were aware of any studies that we may have missed.</p> </section> </section> </section> <section id="CD012433-sec-0057"> <h3 class="title" id="CD012433-sec-0057">Data collection and analysis</h3> <section id="CD012433-sec-0058"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RB and MO) independently assessed the titles and abstracts identified from the searches and excluded any irrelevant studies. The same two authors then reviewed the full‐text papers for inclusion. We resolved any disagreements by discussion; or, if necessary, by asking the third author (AGM) to arbitrate. </p> </section> <section id="CD012433-sec-0059"> <h4 class="title">Data extraction and management</h4> <p>The review authors extracted the following information from included trials. Again, we resolved any disagreements by discussion. </p> <section id="CD012433-sec-0060"> <h5 class="title">Methodological trial design</h5> <p> <ol id="CD012433-list-0005"> <li> <p>Method of concealing randomisation.</p> </li> <li> <p>Method of blinding.</p> </li> <li> <p>Whether any participants had been excluded from reported analyses.</p> </li> <li> <p>Duration of baseline period.</p> </li> <li> <p>Duration of treatment period.</p> </li> <li> <p>Dose(s) of oxcarbazepine tested and potential comparator AED treatment type and dose.</p> </li> </ol> </p> </section> <section id="CD012433-sec-0061"> <h5 class="title">Patient/demographic information</h5> <p> <ol id="CD012433-list-0006"> <li> <p>Number of participants allocated to each treatment group.</p> </li> <li> <p>Age/sex.</p> </li> <li> <p>Seizure types.</p> </li> <li> <p>Seizure frequency during baseline period.</p> </li> <li> <p>Number of background drugs.</p> </li> </ol> </p> <p>Where necessary, we asked original authors to confirm:</p> <p> <ol id="CD012433-list-0007"> <li> <p>the method of randomisation;</p> </li> <li> <p>the total number of participants randomised to each group;</p> </li> <li> <p>the number of participants in each group achieving a 50% or greater reduction in seizure frequency per treatment group; </p> </li> <li> <p>the number of participants having treatment withdrawn post randomisation per treatment group. </p> </li> </ol> </p> <p>And for those excluded:</p> <p> <ol id="CD012433-list-0008"> <li> <p>the reason for exclusion;</p> </li> <li> <p>whether any of those excluded completed the treatment phase;</p> </li> <li> <p>whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatment phase. </p> </li> </ol> </p> </section> <section id="CD012433-sec-0062"> <h5 class="title">Outcomes</h5> <p>We recorded the number of participants experiencing each outcome per randomised group (see <a href="#CD012433-sec-0041">Types of outcome measures</a>). </p> </section> </section> <section id="CD012433-sec-0063"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RB, MO) independently assessed the risk of bias for each trial in accordance with the Cochrane 'Risk of bias' tool, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012433-bbs2-0035" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We discussed any disagreements and, if necessary, sought the opinion of a third review author (AGM). Studies were rated as having a high, low or unclear risk of bias for six domains applicable to RCTs: randomisation sequence; allocation concealment; blinding; incomplete data outcome; selective outcome reporting; and other sources of bias. We also assessed the potential impact of outcome reporting bias by including an Outcome Reporting Bias in Trials (ORBIT) table in the review (<a href="./references#CD012433-bbs2-0041" title="KirkhamJJ , SwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (Clinical Research Ed.)2010;340:365. ">Kirkham 2010</a>). </p> </section> <section id="CD012433-sec-0064"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, such as seizure reduction, seizure freedom, and treatment withdrawal we reported risk ratios (RRs) using 95% confidence intervals. We presented the proportion of participants reporting individual adverse effects as an RR but using 99% confidence intervals in an attempt to compensate for multiple outcome testing. </p> <p>For continuous outcomes — such as cognitive effects and quality of life — in a meta‐analysis, we had ideally planned to report the mean difference. Only one study reported either of these outcomes: it was not necessary or possible, therefore, to complete a meta‐analysis. </p> </section> <section id="CD012433-sec-0065"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include any cross‐over studies in the review; therefore we did not encounter any unit of analysis issues in this regard, and did not require any compensatory methods. </p> <p>For trials with more than one treatment arm (for example, different doses of oxcarbazepine versus a control group), we combined the treatment groups for the main meta‐analysis and then investigated the dosage effects separately during subgroup analysis. </p> </section> <section id="CD012433-sec-0066"> <h4 class="title">Dealing with missing data</h4> <p>In the event of missing data, we sought reasons for this by contacting study authors in order to conclude whether data were missing at random or not. </p> </section> <section id="CD012433-sec-0067"> <h4 class="title">Assessment of heterogeneity</h4> <p>Two authors (RB, MO) independently assessed clinical and methodological heterogeneity. Although we detected some differences in control groups, outcome measures and time scales, we did not detect significant clinical or methodological heterogeneity to the degree to which meta‐analysis would be inappropriate. </p> <p>We visually assessed the clinical and methodological heterogeneity of the included studies. We used the I² statistic and a Chi² test, where applicable, to assess statistical heterogeneity. We judged a Chi² P value of less than 0.10 or I² greater than 50% to indicate statistical heterogeneity. </p> </section> <section id="CD012433-sec-0068"> <h4 class="title">Assessment of reporting biases</h4> <p>We requested protocols from study authors and investigated outcome reporting bias using the ORBIT matrix system (<a href="./references#CD012433-bbs2-0041" title="KirkhamJJ , SwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ (Clinical Research Ed.)2010;340:365. ">Kirkham 2010</a>). </p> <p>To examine publication bias, we searched for unpublished data by carrying out a comprehensive search of multiple sources and requested any unpublished data from study authors. We also looked for small‐study effects to establish the likelihood of publication bias. </p> </section> <section id="CD012433-sec-0069"> <h4 class="title">Data synthesis</h4> <p>We combined data in a fixed‐effect meta‐analysis. Where there was significant clinical, methodological or statistical heterogeneity, however, we combined data in a random‐effects meta‐analysis. </p> </section> <section id="CD012433-sec-0070"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we stratified subgroup analysis by type of control group, age group (adults or children), duration of treatment, and experimental treatment dose. </p> </section> <section id="CD012433-sec-0071"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct any sensitivity analyses as part of this review.</p> <section id="CD012433-sec-0072"> <h5 class="title">Summary of findings and assessment of the certainty of the evidence</h5> <p>We (RB, MO) used the GRADE approach to interpret findings and to assess the certainty of evidence used in the review (<a href="./references#CD012433-bbs2-0054" title="Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org 2. ">Schunemann 2011</a>). We used GRADE Profiler Software (<a href="./references#CD012433-bbs2-0033" title="McMaster University (developed by Evidence Prime). GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime), 2015. ">GRADEPro GDT 2015</a>); and imported data from Review Manager 5 (RevMan 5) to create a 'Summary of findings' table for the main comparison in the review: oxcarbazepine versus control, including the primary and secondary outcomes (see <a href="./full#CD012433-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD012433-bbs2-0050" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We evaluated the evidence across eight criteria (risk of bias; inconsistency; indirectness; imprecision; publication bias; effect size; presence of plausible confounding factors; and dose‐response gradient), according to the GRADE approach, to determine the certainty of evidence. The 'Summary of findings' table thus includes information on overall certainty of the evidence from the trials and information of importance for healthcare decision making. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012433-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012433-sec-0073"></div> <section id="CD012433-sec-0074"> <h3 class="title">Description of studies</h3> <section id="CD012433-sec-0075"> <h4 class="title">Results of the search</h4> <p>The search identified 592 records for potential inclusion; and we found one additional record through other sources (<a href="#CD012433-fig-0001">Figure 1</a>). We contacted Novartis for additional unpublished data, including any unpublished studies that we may not have been aware of. Unfortunately, we received no correspondence. We removed 125 duplicate records; followed by a further 368 records due to irrelevance. We then screened the remaining 100 records to assess their eligibility for inclusion, according to the information provided in the title and abstract of each record. Next, we attempted to retrieve the full texts for the 38 records that remained after the initial screening for the full‐text screening stage. We assessed that 20 records remained eligible for inclusion following the two screening exercises. The 20 records related to six individual trials (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). We extracted the data from these six studies and included them in the subsequent meta‐analysis. </p> <div class="figure" id="CD012433-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram.OXC: Oxcarbazepine" data-id="CD012433-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> <p>OXC: Oxcarbazepine</p> </div> </div> </div> </section> <section id="CD012433-sec-0076"> <h4 class="title">Included studies</h4> <p>The six included studies were all randomised, controlled trials with parallel group design (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). Four of the included studies were placebo‐controlled (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>); whilst two of the studies were alternative‐dose‐controlled (<a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>). All of the included studies, with the exception of one — <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a> — were multi‐centre studies; and all but one study — <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a> — were double‐blind. <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a> was instead rater‐blind. We provide specific details regarding the demographic of the individual treatment groups for each study in the <a href="./references#CD012433-sec-0114" title="">Characteristics of included studies</a> tables. </p> <p><a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> was a multi‐centre, placebo‐controlled, double‐blind study, conducted across 11 countries in 73 centres. Eligible participants were aged 15 to 65 and had drug‐resistant focal epilepsy. Focal seizures could be simple or complex in nature, with or without secondary generalisation. The study consisted of a prospective baseline period, following which participants were randomised to one of four treatment groups: 600 mg/d oxcarbazepine; 1200 mg/d oxcarbazepine; 2400 mg/d oxcarbazepine; or placebo. After randomisation, participants entered a 2‐week up‐titration period followed by a 24‐week maintenance period. Following completion of the trial, there was the option for participants to enter an open‐label extension study. </p> <p><a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> was similarly a multi‐centre, placebo‐controlled, double‐blind study. Eighty‐eight sites were involved in the study and they were located across eight countries: USA, Mexico, Canada, Russia, Poland, Bulgaria, Croatia, and Romania. Participants were aged 18 to 65 and all participants had drug‐resistant focal epilepsy, characterised by uncontrolled focal‐onset seizures, with or without secondary generalisation. The majority of participants were taking two concomitant AEDs during their involvement in the study. Again, this study included an 8‐week prospective baseline period that preceded participant randomisation. Participants were randomised to one of three treatment groups: 1200 mg/d oxcarbazepine; 2400 mg/d oxcarbazepine; or placebo. After randomisation, participants underwent a 4‐week up‐titration period followed by a 12‐week maintenance period. After completing the trial, participants chose whether to enter a 3‐week conversion period which led into an open‐label extension study; or whether to undergo a tapering period to return to their baseline therapy. </p> <p><a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a> was also a multi‐centre, placebo‐controlled, double‐blind study. The trial included 47 sites, distributed across eight countries: Argentina, Chile, Uruguay, Australia, New Zealand, Canada, Israel, and USA. In contrast to the other studies, <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a> only included participants aged 3 to 17 years and thus focused on the efficacy of oxcarbazepine in children. Again, participants were required to have drug‐resistant focal epilepsy, despite receiving one or two concomitant AEDs. Following an 8‐week prospective baseline period, participants were randomised to one of two treatment groups: 30 to 46 mg/kg/d oxcarbazepine or placebo. After being randomised, participants underwent a 2‐week titration period before entering into a 14‐week maintenance period. The study also included optional entry into an open‐label extension study. </p> <p><a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a> was a double‐blind study, similar to the other studies described. In contrast to the other studies, this study was performed at a single centre in Thailand and was an alternative‐dose‐controlled study rather than a placebo‐controlled study. Participants were again recruited from an adult population, aged 18 to 65, who had drug‐resistant focal epilepsy. Focal seizures could be simple, complex, or focal seizures evolving into secondarily generalised seizures. The study likewise had an 8‐week prospective baseline period, following which participants were randomised to one of two treatment groups: either 1200 mg/d or 2400 mg/d oxcarbazepine. Participants then entered a 2‐week up‐titration period which then led into a 14‐week maintenance period. After completion, participants were offered entry into an open‐label extension study. </p> <p><a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> was a multi‐centre, placebo‐controlled, double‐blind study conducted at multiple sites, all of which were located in Japan. Similar to <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>, this trial studied the efficacy of oxcarbazepine in children. Specifically, participants were aged 4 to 14 years with a diagnosis of focal onset seizures which could include simple, complex, and secondarily generalised seizures. Participants were randomised to receive either an oral suspension of either oxcarbazepine (60 mg/ml) or placebo, although information on the precise dosage was not provided. The study comprised an 8‐week prospective baseline period, followed by an 8‐week treatment period. The treatment period included a 2‐week up‐titration phase and a 6‐week maintenance phase. Participants then completed a 3‐ to 5‐week follow‐up period. </p> <p><a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a> was also a multi‐centre study involving 56 centres, distributed across seven countries: USA, Argentina, France, Germany, Brazil, Mexico, and Lithuania. Rather than being placebo‐controlled, the study was instead alternative‐dose‐controlled and participants were randomised to receive either a high dose of oxcarbazepine (60 mg/kg/d) or a low dose of oxcarbazepine (10 mg/kg/d). Interestingly, the study was not double‐blind, but was instead rater‐blind, meaning that the outcome assessor was blinded to treatment. Participants and their caregivers were not blinded. This study was, however, conducted in a very young population of participants, aged one month to four years old. All participants had a diagnosis of focal seizures which included subtypes: simple, complex, and focal evolving to secondarily generalised seizures. Participants were initially screened over a 72‐hour period, prior to commencing a 24‐ to 72‐hour baseline period. The subsequent treatment periods varied in length, dependent on the treatment group. Participants randomised to high‐dose oxcarbazepine (60 mg/kg/d) completed a 26‐day titration period followed by a 9‐day maintenance period, whereas participants randomised to low‐dose oxcarbazepine (10 mg/kg/d) were not required to undergo the 26‐day titration period and, instead, only completed the 9‐day maintenance period. Following the treatment period, there was then a 6‐month open‐label extension phase, included in the study design. </p> </section> <section id="CD012433-sec-0077"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 records at the full‐text screening stage. The 15 excluded records related to 13 individual studies. The reasons for exclusion varied (see summarised in the <a href="./references#CD012433-sec-0115" title="">Characteristics of excluded studies</a> tables). Notably, three records are still awaiting classification. </p> <p>We excluded three records from the review as they were open‐label extension studies with single‐group assignment, and thus lacked a control group (<a href="./references#CD012433-bbs2-0009" title="EUCTR2008‐003334‐19‐BG . Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy [Multicenter, open‐label extension study to evaluate the long‐term safety and tolerability of oxcarbazepine extended‐release (oxc xr) as adjunctive therapy in subjects with refractory partial epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003334‐19/BG (first received 17 May 2010). ">EUCTR2008‐003334‐19‐BG</a>; <a href="./references#CD012433-bbs2-0010" title="GlauserTA , NigroM , SachdeoRC , BeydounA , D'SouzaJ . Long‐term efficacy and safety of adjunctive oxcarbazepine therapy in children with partial‐onset seizures [abstract]. Epilepsia2001;42(Suppl 7):54‐5. ">Glauser 2001</a>; <a href="./references#CD012433-bbs2-0016" title="NCT00918424 . Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects [Long term multiple dose, open‐label, multi‐center study to evaluate the safety and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy]. clinicaltrials.gov/ct2/show/NCT00918424 (first received 11 June 2009). ">NCT00918424</a>). We excluded a further two records as they studied oxcarbazepine as a monotherapy (<a href="./references#CD012433-bbs2-0014" title="NCT00050947 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as monotherapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050947 (first received 01 January 2003). ">NCT00050947</a>; <a href="./references#CD012433-bbs2-0017" title="NCT01891890 . Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) (COPE) [Cognitive AED Outcomes in pediatric localization related epilepsy (COPE)]. clinicaltrials.gov/ct2/show/NCT01891890 (first received 03 July 2013). ">NCT01891890</a>); whilst another record used oxcarbazepine to replace carbamazepine in participants' drug regime and was therefore deemed irrelevant (<a href="./references#CD012433-bbs2-0011" title="HoutkooperMA , LammertsmaA , MeyerJW , GoedhartDM , MeinardiH , vanOorschotCA , et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?. Epilepsia1987;28(6):693‐8. ">Houtkooper 1987</a>). The latter study also included a number of participants with generalised‐onset seizures which did not comply with the review inclusion criteria. We found another record, Gillham 1993, to be linked to another record, a study by <a href="./references#CD012433-bbs2-0013" title="GillhamRA , McKeePJW , BrodieMJ . Oxcarbazepine and cognitive function after a single dose and during a double‐blind placebo‐controlled cross‐over study. Epilepsia1993;34(Suppl 2):122. McKeePJ , BlacklawJ , ForrestG , GillhamRA , WalkerSM , ConnellyD , et al. A double‐blind, placebo‐controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. British Journal of Clinical Pharmacology1994;37(1):27‐32. ">McKee 1994</a>. We excluded both records from the review as they were deemed to be irrelevant. The study primarily focused on investigating the pharmacokinetics of oxcarbazepine and initially used oxcarbazepine as a monotherapy rather than as an adjunctive therapy. We excluded an additional record, a trial by <a href="./references#CD012433-bbs2-0018" title="DulacO , D'SouzaJ , MotteJ . Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy. Annals of Neurology2001;50(Suppl 1):S104. ReyE , BulteauC , MotteJ , TranA , SturmY , D'SouzaJ , et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. Journal of Clinical Pharmacology2004;44(11):1290‐300. ">Rey 2004</a>, and a linked record, a poster abstract by Dulac 2001, after it was revealed that the full‐text record — <a href="./references#CD012433-bbs2-0018" title="DulacO , D'SouzaJ , MotteJ . Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy. Annals of Neurology2001;50(Suppl 1):S104. ReyE , BulteauC , MotteJ , TranA , SturmY , D'SouzaJ , et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. Journal of Clinical Pharmacology2004;44(11):1290‐300. ">Rey 2004</a> — did not provide data for any of the outcomes defined in the review and also focused on the pharmacokinetics of oxcarbazepine. This study also included participants with generalised epilepsy, which again made it ineligible for inclusion as the authors did not report the outcomes stratified by primary seizure type. We excluded one record because, upon inspection of the full‐text, we discovered that the record was a meta‐analysis of safety data taken from 21 studies, and was not a randomised controlled trial (<a href="./references#CD012433-bbs2-0012" title="KutluayE , McCagueK , D'SouzaJ , BeydounA . Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy &amp; Behavior2003;4(2):175‐80. ">Kutluay 2003</a>). </p> <p>We excluded the remaining four studies because there were no results available for the studies (<a href="./references#CD012433-bbs2-0007" title="EUCTR2004‐002260‐25‐AT . OXC retard [A randomized, phase III, double blind, active‐controlled, two‐armed, multi‐center study on efficacy and safety of once‐daily oxcarbazepine (‐modified release formulation) versus twice‐daily oxcarbazepine (Timox®) in 300 patients with partial onset epilepsy]. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐002260‐25/AT (first received 21 February 2005). ">EUCTR2004‐002260‐25‐AT</a>; <a href="./references#CD012433-bbs2-0008" title="EUCTR2006‐003834‐14‐DE . EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy [Safety and efficacy of novel modified release formulation of oxacarbazepine (oxc mr) vs an immediate release oxacarbazepine (oxc ir) product in patients with partial epilepsy. Open‐labelled, controlled, parallel group, flexible dose, multicentre study]. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐003834‐14/DE (first received 11 August 2011). ">EUCTR2006‐003834‐14‐DE</a>; <a href="./references#CD012433-bbs2-0015" title="NCT00391534 . EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy [Safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) vs an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy]. clinicaltrials.gov/ct2/show/NCT00391534 (first received 24 October 2006). ">NCT00391534</a>; <a href="./references#CD012433-bbs2-0019" title="SteinhoffBJ , StefanH , Schulze‐BonhageA , HueberR , PaulusW , WangemannM , et al. [Slow release versus immediate release oxcarbazepine in difficult‐to‐treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study]. Der Nervenarzt2012;83(10):1292‐9. ">Steinhoff 2012</a>). Notably, three records corresponded to studies which had been terminated early due to low recruitment and, therefore, no data were available (<a href="./references#CD012433-bbs2-0008" title="EUCTR2006‐003834‐14‐DE . EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy [Safety and efficacy of novel modified release formulation of oxacarbazepine (oxc mr) vs an immediate release oxacarbazepine (oxc ir) product in patients with partial epilepsy. Open‐labelled, controlled, parallel group, flexible dose, multicentre study]. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐003834‐14/DE (first received 11 August 2011). ">EUCTR2006‐003834‐14‐DE</a>; <a href="./references#CD012433-bbs2-0015" title="NCT00391534 . EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy [Safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) vs an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy]. clinicaltrials.gov/ct2/show/NCT00391534 (first received 24 October 2006). ">NCT00391534</a>; <a href="./references#CD012433-bbs2-0019" title="SteinhoffBJ , StefanH , Schulze‐BonhageA , HueberR , PaulusW , WangemannM , et al. [Slow release versus immediate release oxcarbazepine in difficult‐to‐treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study]. Der Nervenarzt2012;83(10):1292‐9. ">Steinhoff 2012</a>). Similarly results were not reported for the other record; consequently we also had to exclude this record from the review (<a href="./references#CD012433-bbs2-0007" title="EUCTR2004‐002260‐25‐AT . OXC retard [A randomized, phase III, double blind, active‐controlled, two‐armed, multi‐center study on efficacy and safety of once‐daily oxcarbazepine (‐modified release formulation) versus twice‐daily oxcarbazepine (Timox®) in 300 patients with partial onset epilepsy]. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐002260‐25/AT (first received 21 February 2005). ">EUCTR2004‐002260‐25‐AT</a>). Additionally, after we studied the EU clinical trial registration for the latter record (<a href="./references#CD012433-bbs2-0007" title="EUCTR2004‐002260‐25‐AT . OXC retard [A randomized, phase III, double blind, active‐controlled, two‐armed, multi‐center study on efficacy and safety of once‐daily oxcarbazepine (‐modified release formulation) versus twice‐daily oxcarbazepine (Timox®) in 300 patients with partial onset epilepsy]. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐002260‐25/AT (first received 21 February 2005). ">EUCTR2004‐002260‐25‐AT</a>), it appeared that a certain proportion of participants on the study received oxcarbazepine as a monotherapy, not as an add‐on ― therefore we suspected that the study was ineligible for inclusion, regardless. </p> <p>We further recognised that for another three of the records highlighted in the searches, we required additional information before being able to decide whether they were eligible for inclusion in the review (<a href="./references#CD012433-bbs2-0020" title="CTRI/2010/091/000100 . A Clinical Trial to Investigate Efficacy and Safety of Eslicarbazepine Acetate Tablet versus Oxcarbazepine SR Tablet Eslicarbazepine as an Adjunctive Treatment in Patients With Refractory Epilepsy Suffering From Partial Onset Seizures With or Without Secondary Generalisation [A Multicenter, Randomized Open‐Label, Comparative, Prospective Clinical Trial to Investigate Efficacy and Safety of Eslicarbazepine Acetate Tablet versus Oxcarbazepine SR Tablet as an Adjunctive Treatment in Patients With Refractory Epilepsy Suffering From Partial Onset Seizures With or Without Secondary Generalisation]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1315 (first received 13 September 2010). ">CTRI/2010/091/000100</a>; <a href="./references#CD012433-bbs2-0021" title="CTRI/2010/091/001194 . Clinical Study to evaluate efficacy and safety of Eslicarbazepine acetate as an adjunctive therapy in partial‐onset seizures. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1992 (first received 9 August 2010). ">CTRI/2010/091/001194</a>; <a href="./references#CD012433-bbs2-0022" title="CTRI/2010/091/006085 . 13‐week study for evaluation of efficacy and safety of in‐aqul‐002 tablet compared to oxcarbazepine sustained‐release tablet as adjunctive treatment in adult patients with refractory partial‐onset seizures [An open label, randomized, parallel group, prospective, multicentre clinical trial for evaluation of efficacy and safety of IN‐AQUL‐002 in comparison with oxcarbazepine sustained‐release as adjunctive treatment in adult patients with refractory partial‐onset seizures]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=2479 (first received 22 December 2010). ">CTRI/2010/091/006085</a>). These records have, therefore, been acknowledged under studies awaiting classification (See <a href="./references#CD012433-sec-0116" title="">Characteristics of studies awaiting classification</a> tables). At the time of publication of this review, we had requested additional information for the studies awaiting classification but had not yet received it. </p> </section> </section> <section id="CD012433-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged that three of the included studies were at an unclear risk of bias overall (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>), and rated that the remaining three studies were at a high risk of bias (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). The rating for the risk of bias, according to each bias domain, for each individual study included, is described in detail below and can be found summarised in <a href="#CD012433-fig-0002">Figure 2</a> and <a href="#CD012433-fig-0003">Figure 3</a> as well as in the 'Risk of bias' tables within the <a href="./references#CD012433-sec-0114" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD012433-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012433-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012433-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012433-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012433-sec-0079"> <h4 class="title">Allocation</h4> <p>We judged that three of the included studies had a low risk of bias with regards to random sequence generation (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). One study specified that a pseudo‐random number generator was used (<a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>); whilst another study stated use of a computer‐generated schedule for randomisation (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>). The third study claimed that randomisation was automated by an interactive voice response system which automated the successful randomisation of participants (<a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>). </p> <p>Similarly, we assessed these three studies to be at low risk of bias, resulting from allocation concealment (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Two studies used an interactive voice response system which guarantees allocation concealment (<a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). The other study employed a phone call system were the investigator would call the central office for allocation of a participant, again ensuring allocation concealment (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>). </p> <p>We determined the other three studies to be at unclear risk of bias across the two selection bias domains — random sequence generation and allocation concealment — as no information regarding either domain was provided by the study publications (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). </p> </section> <section id="CD012433-sec-0080"> <h4 class="title">Blinding</h4> <p>We assessed that four of the included studies were at low risk of performance and detection bias (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Three of the studies used matching placebo, achieved by using capsules and tablets identical in appearance to the active oxcarbazepine tablets (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). For these three studies, participants were required to keep a seizure diary and therefore acted as the outcome assessors (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Given the successful blinding of both participants and personnel, specifically those responsible for data entry and analysis ensured by the matching placebo, we judged that outcome assessment would be effectively blinded. For this reason, we judged that these three studies were at low risk of both performance and detection bias (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). </p> <p>The fourth study did not use any blinding method but the participants involved in the study were all below the age of four so we agreed that blinding was unlikely to influence the responsiveness of this population of participants (<a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>). Accordingly, we awarded the study a low risk of bias judgement for performance bias. With regards to outcome assessment, an independent paediatric neurologist, not otherwise involved in the study, assessed and recorded seizures. Consequently, we also judged this study to be at low risk of detection bias (<a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>). </p> <p>No information regarding the blinding of either participants or of outcome assessors was provided by a further two of the study publications (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). Notably, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> included adult participants and <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> included children up to the age of 14 who could have been affected by a lack of or inadequate blinding. We thus assessed that these two studies were at unclear risk of bias for the two domains of performance bias and detection bias. </p> </section> <section id="CD012433-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>Although five of the included studies utilised a modified intention‐to‐treat population for their efficacy analysis and all fully reported attrition (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>), we only rated one of these studies to be at low risk of attrition bias (<a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>). The study by <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a> featured an overall attrition rate of 10.2% and the attrition was evenly distributed between the two treatment groups — high‐dose and low‐dose oxcarbazepine. In contrast two of the studies, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> and <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>, reported very high attrition rates overall (42.5% and 32.2%, respectively). Most notably, the rate of attrition was not evenly distributed between the treatment groups. In both studies, the attrition rate was considerably higher in the highest oxcarbazepine dose group. For example in the study by <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>, the attrition rate was 73.6% for the treatment group receiving 2400 mg/d oxcarbazepine compared to 22.5% in the group given the lowest dose, 600 mg/d oxcarbazepine. Additionally, <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> employed a highly modified intention‐to‐treat population for their efficacy analyses which excluded nearly 8% of the study population from their subsequent analyses. As a result we judged that both <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> and <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> were at high risk of attrition bias. </p> <p>Furthermore, in both <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> and <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> approximately a quarter of the participants who were randomised to the highest dose treatment group (2400 mg/d oxcarbazepine) actually received a lower dose of 1800 mg/d oxcarbazepine after being down‐titrated. As a consequence, the data reported regarding the tolerability and efficacy of 2400 mg/d oxcarbazepine is likely misrepresented, and could potentially be regarded as misleading. </p> <p>The remaining two studies, <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a> and <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>, had acceptable study attrition rates — 11.6% and 10.1% attrition, respectively. Attrition was not evenly distributed between the two treatment groups in either study, however. In the study by <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>, the attrition rate for the oxcarbazepine treatment group was double that of the placebo treatment group. For the <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> study, the rate of attrition was nine times higher in the oxcarbazepine group than in the placebo group (nine versus one participant). For both studies the attrition rate remained below 20%, even in the oxcarbazepine treatment group (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). For this reason we judged the two studies to be at unclear risk of bias, rather than at high risk of bias (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). </p> <p>Despite not conducting an intention‐to‐treat efficacy analysis, we deemed the study by <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a> to be at low risk of attrition bias. <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a> conducted a 'per protocol' analysis, rather than an intention‐to‐treat analysis. This, however, only excluded four participants from the study analyses. The overall attrition rate for this study was relatively low (10.3%) and was evenly distributed between treatment groups. Furthermore, we were able to reinstate the excluded participants in our intention‐to‐treat analysis conducted in this review and, therefore, the attrition did not influence our findings or conclusions. As a result, we assessed the risk of attrition bias as low for <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>. </p> </section> <section id="CD012433-sec-0082"> <h4 class="title">Selective reporting</h4> <p>We judged all six included studies to be at low risk of reporting bias (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). Although we were unable to retrieve trial protocols for any of the studies, the outcomes defined in the Methods section for each of the five published studies were all clearly and fully reported in the respective Results sections (<a href="#CD012433-fig-0004">Figure 4</a>) (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Similarly for the <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> study, the results of the outcomes defined under the 'study details' of the relevant <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> web page were then fully reported under the 'Results' tab. We therefore had no reason to suspect reporting bias in either instance. </p> <div class="figure" id="CD012433-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="ORBIT Matrix for primary, secondary and harm (safety) outcomes to investigate reporting bias" data-id="CD012433-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>ORBIT Matrix for primary, secondary and harm (safety) outcomes to investigate reporting bias </p> </div> </div> </div> </section> <section id="CD012433-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>We determined that three of the included studies were free of any other sources of bias (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). We therefore awarded these three studies a low risk of bias rating for this domain. </p> <p>By contrast, we rated the <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> study as being at an unclear risk of bias regarding other sources of bias. We do not have a full, detailed publication for this study, hence we are unable to either identify or dismiss any other potential sources of bias. We also assessed <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a> to be at unclear risk of other bias because the range of doses used was notably different to the target dose specified in the Methods section. Specifically, the lowest dose used was 6.4 mg/kg/d which is dramatically lower than the 30 mg/kg/d suggested dose. Additionally, we assessed the study by <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a> to be at high risk of other potential sources of bias due to the significantly longer treatment period noted for the high‐dose oxcarbazepine group, compared to the low‐dose oxcarbazepine group. </p> </section> </section> <section id="CD012433-sec-0084"> <h3 class="title" id="CD012433-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD012433-tbl-0001"><b>Summary of findings for the main comparison</b> Oxcarbazepine compared to control for drug‐resistant focal epilepsy</a> </p> <p>Importantly, for the purposes of our analyses in this review we reinstated any participants that had previously been excluded from the analyses conducted within the original trial publications to fully adhere to the intention‐to‐treat population principle. Within the trial publications, modified intention‐to‐treat populations had been implemented which incorrectly excluded participants who would normally be eligible for inclusion in intention‐to‐treat analyses. Unless specified, a fixed‐effect model was used for the analyses performed. In instances where we identified significant heterogeneity, we used a random‐effects model; this is declared in the text below. </p> <p>A summary of the most important outcomes for the main comparison, oxcarbazepine versus control, are presented in the <a href="./full#CD012433-tbl-0001">summary of findings Table for the main comparison</a>. For the purposes of this comparison, control treatment could be placebo, an alternative antiepileptic drug, or a different dose of oxcarbazepine. Specifically, for the studies included in this review the control treatment was either placebo or a different dose of oxcarbazepine. We did not identify any eligible studies that compared oxcarbazepine to an alternative antiepileptic drug. For this comparison, we pooled all data regardless of dose of oxcarbazepine used, age of participants, or treatment duration. </p> <p>Subsequent to completing the meta‐analysis for the main comparison, we then considered how these variables might have affected the effect size estimates and whether these variables were possible sources of heterogeneity by conducting various subgroup analyses. Based on the study data collected, we stratified data for the subgroup analyses according to: control group used (placebo and alternative oxcarbazepine dose subgroups); age group included (adults and children); duration of treatment period (8 weeks or less, 16 weeks, and 26 weeks); and oxcarbazepine dose (600 mg, 1200 mg, and 2400 mg oxcarbazepine). </p> <section id="CD012433-sec-0085"> <h4 class="title">Median percentage seizure reduction per 28 days</h4> <p>Median values cannot be incorporated into a meta‐analysis. As a result the outcome — median percentage seizure reduction — must be described narratively. Five studies, consisting of 1494 participants, reported median percentage seizure reduction per 28 days for participants randomised to oxcarbazepine (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). The median percentage seizure reduction for participants randomised to placebo add‐on treatment was reported by three studies (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). The values reported ranged from 7.6% to 28.7% seizure reduction, with two of the three studies specifically reporting percentage reductions of less than 10% (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>). The median percentage seizure reduction for participants randomised to experimental oxcarbazepine treatment ranged from 26% to 83.3%. Notably, in studies which tested multiple doses of oxcarbazepine (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>), the higher doses were associated with a greater median percentage reduction in seizure frequency. For example in the <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> study, the median percentage seizure reductions were 26%, 40% and 50% for participants allocated to 600 mg/d, 1200 mg/d and 2400 mg/d oxcarbazepine, respectively. Importantly, for each study that described this outcome the median percentage seizure reduction reported was consistently higher in experimental oxcarbazepine treatment group than in the control group. </p> </section> <section id="CD012433-sec-0086"> <h4 class="title">50% or greater reduction in seizure frequency</h4> <p>All six studies (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>), involving 1593 participants, contributed to <a href="./references#CD012433-fig-0005" title="">Analysis 1.1</a>. We detected significant heterogeneity within the data set (P = 0.006, I² = 70%) and consequently used a random‐effects model to combine the data. The responder rate was significantly higher in the experimental oxcarbazepine group, compared to the control group (RR 1.80, 95% CI 1.27 to 2.56, P &lt; 0.001). We completed subgroup analysis stratified by the nature of the control group (<a href="./references#CD012433-fig-0027" title="">Analysis 2.1</a>); the age of the clinical sample (<a href="./references#CD012433-fig-0030" title="">Analysis 3.1</a>); the duration of the treatment period (<a href="./references#CD012433-fig-0033" title="">Analysis 4.1</a>); and the dose of experimental oxcarbazepine (<a href="./references#CD012433-fig-0036" title="">Analysis 5.1</a>). </p> <p>Subgroup analyses stratified by the type of control group (P = 0.03, I² = 79.8%; <a href="./references#CD012433-fig-0027" title="">Analysis 2.1</a>) and by the duration of the treatment period (P = 0.01, I² = 77.9%; <a href="./references#CD012433-fig-0033" title="">Analysis 4.1</a>) demonstrated a significant subgroup effect for the responder rate. This implies that both the type of control group used and the duration of the treatment period might explain some of the statistical heterogeneity observed. Interestingly, a substantial amount of statistical heterogeneity remained despite stratifying the data according to the clinical and design‐dependent subgroups. With respect to the control group used, a much larger, statistically significant treatment effect was observed in studies utilising a placebo‐controlled design (RR 2.09, 95% CI 1.69 to 2.59, P &lt; 0.001) compared to the insignificant effect observed in studies using an alternative‐dose‐controlled study design (RR 1.36, 95% CI 0.99 to 1.86, P = 0.06; <a href="./references#CD012433-fig-0027" title="">Analysis 2.1</a>). Notably, only two small‐sample studies contributed data to the alternative‐dose‐controlled subgroup. The results between the two studies were nevertheless very consistent. Specifically, the magnitude of the effect size observed was much greater with a treatment period of 26 weeks (RR 3.09, 95% CI 2.06 to 4.64, P &lt; 0.001) than with a treatment period of 16 weeks or less (RR 1.51, 95% CI 1.20 to 1.92, P &lt; 0.001; <a href="./references#CD012433-fig-0033" title="">Analysis 4.1</a>). It should be noted, however, that the data for the 26‐week duration subgroup was taken from a single study (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>). Subgroup analysis stratified by the age of participants did not reveal a significant subgroup effect (P = 0.49) (<a href="./references#CD012433-fig-0030" title="">Analysis 3.1</a>). Although it was not possible to conduct a test for subgroup differences for <a href="./references#CD012433-fig-0036" title="">Analysis 5.1</a> (subgroup analysis stratified by the dose of experimental oxcarbazepine used), the magnitude of change in risk ratios between doses was not sufficiently great. Notably, the confidence intervals for each risk ratio calculated considerably overlapped and there was no clear clustering of data points for each subgroup. This suggests that there is not a dose‐dependent subgroup effect for the outcome of 50% or greater reduction in seizure frequency. </p> </section> <section id="CD012433-sec-0087"> <h4 class="title">Adverse effects</h4> <p>We investigated the incidence rate of 19 different adverse effects. There was no statistically significant difference in the incidence of 11 of the suggested adverse effects detected between participants randomised to the experimental oxcarbazepine group and those randomised to the control group. The 11 adverse effects were: ataxia (<a href="./references#CD012433-fig-0006" title="">Analysis 1.2</a>), nausea (<a href="./references#CD012433-fig-0009" title="">Analysis 1.5</a>), headache (<a href="./references#CD012433-fig-0011" title="">Analysis 1.7</a>), hyponatraemia (<a href="./references#CD012433-fig-0012" title="">Analysis 1.8</a>), rash (<a href="./references#CD012433-fig-0015" title="">Analysis 1.11</a>), tremor (<a href="./references#CD012433-fig-0016" title="">Analysis 1.12</a>), pyrexia (<a href="./references#CD012433-fig-0017" title="">Analysis 1.13</a>), abdominal pain (<a href="./references#CD012433-fig-0019" title="">Analysis 1.15</a>), viral infection (<a href="./references#CD012433-fig-0021" title="">Analysis 1.17</a>), abnormal vision (<a href="./references#CD012433-fig-0023" title="">Analysis 1.19</a>), and upper respiratory tract infection (<a href="./references#CD012433-fig-0024" title="">Analysis 1.20</a>). </p> <p>The remaining eight adverse effects investigated are described below.</p> <p> <ol id="CD012433-list-0009"> <li> <p>Dizziness was reported in four studies, consisting of 1336 participants (<a href="./references#CD012433-fig-0007" title="">Analysis 1.3</a>). The incidence of dizziness was significantly greater in the experimental oxcarbazepine group compared to the control group (RR 2.58, 99% CI 1.81 to 3.68, P &lt; 0.001). </p> </li> <li> <p>Fatigue was reported in four studies, consisting of 1336 participants (<a href="./references#CD012433-fig-0008" title="">Analysis 1.4</a>). The incidence of fatigue was significantly higher in the experimental oxcarbazepine group than in the control group (RR 1.88, 99% CI 1.07 to 3.32, P = 0.004). </p> </li> <li> <p>Somnolence was reported by all six studies, involving a total of 1593 participants (<a href="./references#CD012433-fig-0010" title="">Analysis 1.6</a>). Significant heterogeneity (P = 0.03, I² = 59%) was detected within the data set. Consequently, a random‐effects model was used for the analysis. Participants in the experimental oxcarbazepine group were twice as likely to experience somnolence as participants in the control group (RR 2.03, 99% CI 1.17 to 3.54, P = 0.001). </p> </li> <li> <p>Vertigo was reported in two studies, involving 793 participants (<a href="./references#CD012433-fig-0013" title="">Analysis 1.9</a>). Participants in the experimental oxcarbazepine group were over four times more likely to experience vertigo than those in the control group (RR 4.62, 99% CI 1.32 to 16.13, P = 0.002). </p> </li> <li> <p>Diplopia was reported by five studies, including 1465 participants (<a href="./references#CD012433-fig-0014" title="">Analysis 1.10</a>). Participants in the experimental oxcarbazepine group were over five times more at risk of experiencing diplopia than those in the control group (RR 5.50, 99% CI 2.83 to 10.68, P &lt; 0.001). </p> </li> <li> <p>Abnormal gait was reported by only two studies with 961 participants included in the analysis (<a href="./references#CD012433-fig-0018" title="">Analysis 1.14</a>). Participants in the experimental oxcarbazepine group were over five times more likely to experience abnormal gait changes than those in the control group (RR 5.53, 99% CI 1.74 to 17.61, P &lt; 0.001). </p> </li> <li> <p>Nystagmus was reported by two studies, involving 961 participants (<a href="./references#CD012433-fig-0020" title="">Analysis 1.16</a>). The incidence of nystagmus was over four times greater in the experimental oxcarbazepine group than in the control group (RR 4.56, 99% CI 1.90 to 10.94, P &lt; 0.001). </p> </li> <li> <p>Vomiting was reported in all six studies, including a total of 1593 participants (<a href="./references#CD012433-fig-0022" title="">Analysis 1.18</a>). Significant heterogeneity (P = 0.06, I² = 54%) was detected within the data set. A random‐effects model was, therefore, used for the analysis. Participants receiving experimental oxcarbazepine treatment were significantly more likely to experience vomiting than participants receiving control treatment (RR 2.55, 99% CI 1.20 to 5.42, P = 0.001). </p> </li> </ol> </p> </section> <section id="CD012433-sec-0088"> <h4 class="title">Seizure freedom</h4> <p>Five of the included studies involving 1494 participants contributed to the following outcome analysis (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Significant heterogeneity was detected within the data set (P = 0.08, I² = 51%); therefore, we utilised a random‐effects model for the outcome analysis. Participants randomised to the experimental oxcarbazepine group were nearly three times more likely to attain seizure freedom than were participants randomised to a control group (RR 2.86, 95% CI 1.19 to 6.87, P = 0.02). </p> <p>We conducted multiple subgroup analyses to explore the possible reasons for the observed heterogeneity. Subgroup analysis stratified by control group, specifically whether the study was placebo‐controlled or alternative‐dose‐controlled, displayed significant heterogeneity between the two subgroups (P = 0.02, I² = 81.1%, <a href="./references#CD012433-fig-0028" title="">Analysis 2.2</a>). Notably, in placebo‐controlled studies participants receiving oxcarbazepine were six times more likely to achieve seizure freedom than participants receiving placebo (RR 6.14, 95% CI 2.62 to 14.41, P &lt; 0.01). In contrast, a significant difference in the likelihood of achieving seizure freedom was not detected between participants receiving high‐dose versus low‐dose oxcarbazepine in alternative‐dose‐controlled studies (RR 1.45, 95% CI 0.58 to 3.62, P = 0.08). </p> <p>Subgroup analysis stratified by age of study population (P = 0.10; <a href="./references#CD012433-fig-0031" title="">Analysis 3.2</a>) and duration of treatment period (P = 0.08; <a href="./references#CD012433-fig-0034" title="">Analysis 4.2</a>) did not display a significant subgroup effect for the outcome 'seizure freedom'. Despite this, the risk ratio calculated for adults (RR 5.19, 95% CI 2.29 to 11.75) was notably larger compared to that calculated for children (RR 2.16, 95% CI 1.13 to 4.14). Likewise, within the treatment period subgroup analysis, 26 weeks' treatment period demonstrated a much larger treatment effect (RR 20.26, 95% CI 2.83 to 145.02) for oxcarbazepine compared to placebo over the shorter treatment duration lengths (8 weeks or less: RR 1.90, 95% CI 0.96 to 3.76; 16 weeks: RR 2.41, 95% CI 1.05 to 5.52). Specifically, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> was the only study to supply data to the 26‐week treatment period subgroup and was also one of only three studies to contribute data to the adult subgroup. <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> predicted a very large risk ratio (RR 20.26, 95% CI 2.83 to 145.02) which most likely skewed the adult subgroup. Whilst it is clear that this result is an outlier compared to the other results within the adult subgroup, it is still worth considering that adults could potentially respond better to oxcarbazepine than children. Similar observation apply to treatment duration for seizure freedom. </p> <p>Subgroup analysis stratified by dose of experimental oxcarbazepine did not demonstrate a clear effect of dose on the estimated effect (<a href="./references#CD012433-fig-0037" title="">Analysis 5.2</a>). Again, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> predicted much larger treatment effects, dependent on dose, compared to the other included studies in the subgroups. Due to the heterogeneity and inconsistency of the data within the individual dose subgroups, we did not consider that dose explained the heterogeneity observed across the entire dataset. </p> </section> <section id="CD012433-sec-0089"> <h4 class="title">Treatment withdrawal</h4> <p>All six included studies (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>), comprising 1593 participants, contributed to this outcome analysis. We did not detect significant heterogeneity (P = 0.55, I² = 0%) within this data set for the main comparison — oxcarbazepine versus control — and therefore we continued to utilise the fixed‐effect model for this outcome analysis. Participants receiving experimental oxcarbazepine treatment were significantly more likely to withdraw from treatment. Specifically, participants receiving experimental oxcarbazepine were 75% more likely than participants receiving the control treatment to withdraw from treatment (RR 1.75, 95% CI 1.44 to 2.13, P &lt; 0.001; <a href="./references#CD012433-fig-0026" title="">Analysis 1.22</a>). </p> <p>Although we did not detect any statistical heterogeneity within the data set, we continued to conduct subgroup analysis to determine whether any undetected clinical or methodological heterogeneity might exist. Although we were unable to conduct the test for subgroup differences for the subgroup analysis stratified by the experimental dose of oxcarbazepine used (<a href="./references#CD012433-fig-0038" title="">Analysis 5.3</a>), due to the overlap in placebo participants between subgroups, we were able to identify clear differences between the subgroups, based on the risk ratios calculated. The rate of treatment withdrawal was significantly higher for participants randomised to both 1200 mg/d (RR 1.95, 95% CI 1.50 to 2.52, P &lt; 0.001) and 2400 mg/d oxcarbazepine (RR 2.38, 95% CI 1.92 to 2.94, P &lt; 0.001). Participants randomised to both treatment groups were approximately twice as likely to withdraw from treatment as those receiving placebo. On the other hand, the treatment withdrawal rates for participants receiving 600 mg/d oxcarbazepine and those receiving control were not significantly different (RR 0.79, 95% CI 0.55 to 1.15, P = 0.22). </p> <p>Subgroup analysis stratified by the type of control group (P = 0.52; <a href="./references#CD012433-fig-0029" title="">Analysis 2.3</a>), the age of the clinical sample (P = 0.29; <a href="./references#CD012433-fig-0032" title="">Analysis 3.3</a>), and the duration of treatment period (P = 0.51; <a href="./references#CD012433-fig-0035" title="">Analysis 4.3</a>) did not display a significant subgroup effect for the outcome 'treatment withdrawal'. </p> </section> <section id="CD012433-sec-0090"> <h4 class="title">Quality of life and cognitive effects</h4> <p>Only <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>, involving 366 participants, measured and reported quality of life. <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> used the Quality of Life in Epilepsy (QOLIE‐31) questionnaire which includes a subscale score for cognitive functioning. This enabled the study to assess both the quality of life of participants and, potentially, any perceived cognitive effects. <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a> reported that the mean total QOLIE‐31 and subscale scores did not decrease from baseline for any of the treatment groups: 1200 mg/d oxcarbazepine, 2400 mg/d oxcarbazepine, or placebo. This highlights that, most importantly, there was no decrease in quality of life resulting from active treatment. The 1200 mg/d treatment group did, however, demonstrate a significantly smaller increase in the QOLIE‐31 subscale of Cognitive Functioning. Additionally, there was a significantly smaller increase in the Medication Effects for both the 1200 mg/d oxcarbazepine and 2400 mg/d oxcarbazepine treatments groups, compared to placebo. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012433-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012433-sec-0091"></div> <section id="CD012433-sec-0092"> <h3 class="title" id="CD012433-sec-0092">Summary of main results</h3> <p>This review included data from six randomised controlled trials (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>), involving a total of 1593 participants. We judged that three of the included studies were at unclear risk of bias (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>); and the other three were at high risk of bias (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Most of the concerns about bias arose from the lack of details provided regarding the randomisation and allocation concealment of participants. There were also concerns about the high attrition rate noted in several of the studies. The attrition rate was especially problematic in the treatment groups receiving the higher doses of oxcarbazepine. </p> <p>Treatment with oxcarbazepine was associated with an increased responder rate (the number of participants achieving a 50% or greater reduction in seizure frequency), as well as an increased incidence of seizure freedom compared to control treatment. Both of these outcomes were, however, derived from low‐certainty evidence, according to GRADE assessment, meaning that we cannot be certain about the accuracy of these results. Interestingly, when the data were subjected to subgroup analyses, both outcomes were associated with a statistically significant subgroup effect when stratified by the type of control group utilised (placebo or alternative dose). Specifically, experimental oxcarbazepine was revealed to have a much greater treatment effect with regards to seizure freedom and responder rate when compared to placebo control rather than when compared to an alternative, lower dose of oxcarbazepine. </p> <p>Additionally, the responder rate also demonstrated a significant subgroup effect when stratified by the duration of the treatment period. Oxcarbazepine given over the longest treatment period (26 weeks) demonstrated a much larger treatment effect size for responder rate than oxcarbazepine given over the shorter treatment periods. Importantly, however, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> was the only study which had a treatment period of 26 weeks and was, therefore, the only study to contribute data to this subgroup for the analysis. Although the study by <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> contained a large sample size (694 participants), the fact that the subgroup analysis is derived from a single study should be considered when interpreting the results. Of further significance, <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> was also a placebo‐controlled study. As previously described, subgroup analysis according to control group revealed that oxcarbazepine was shown to have a greater therapeutic effect when compared to placebo, and therefore it is possible that these two trial characteristics — the nature of the control group and the treatment duration — could be confounding the results between the two subgroup analyses (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). </p> <p>With regards to tolerability, treatment with experimental oxcarbazepine increased the treatment withdrawal rate compared to that observed with control treatment. The evidence was of moderate certainty for this outcome, suggesting that this finding is likely to be accurate. Subgroup analyses for the outcome 'treatment withdrawal' revealed clear differences in the treatment effect predicted for subgroups when the data were stratified according to dose of experimental oxcarbazepine. The largest oxcarbazepine dose, 2400 mg/d, was associated with a larger treatment withdrawal rate compared to control than was 1200 mg/d or 600 mg/d oxcarbazepine. Treatment with experimental oxcarbazepine was furthermore associated with an increased incidence rate for several of the adverse effects included in the review, namely: dizziness, fatigue, somnolence, vertigo, diplopia, abnormal gait, nystagmus, and vomiting. </p> <p>Notably, we analysed data for a total of 19 adverse effects and consequently the likelihood of type I and type II statistical errors occurring was significantly increased. Although care must therefore be taken when interpreting the results, the findings regarding the adverse effects are consistent with the increased treatment withdrawal rate observed. In short‐term studies, treatment withdrawal most commonly relates to adverse effects experienced rather than reflecting a lack of efficacy. This consequently implies that the increased occurrence of adverse effects is a true effect of oxcarbazepine treatment. </p> <p>To summarise, our review has indicated that oxcarbazepine may display a therapeutic effect, as demonstrated by the significantly increased responder and seizure freedom rate compared to control. Uncertainty about this finding arises, however, from the low‐certainty evidence used to derive this finding. Our review has also highlighted issues with the tolerability of oxcarbazepine, specifically at higher dosages, which is reflected in the increased treatment withdrawal rate. </p> </section> <section id="CD012433-sec-0093"> <h3 class="title" id="CD012433-sec-0093">Overall completeness and applicability of evidence</h3> <p>As part of this review, we had hoped to explore the effect of oxcarbazepine on quality of life and cognition. Unfortunately, however, only one of the included studies investigated and reported quality of life (<a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). Notably, the questionnaire used to assess quality of life did include an element whereby participants were asked to evaluate their own cognition; this clearly requires self‐report, however, and is not a thorough examination of cognitive ability. As a result, we are not adequately informed to comment on the effects of oxcarbazepine on either outcome. A thorough neuropsychological assessment with more rigorous cognitive testing, focusing on assessing memory, attention and psychomotor speed, would be necessary to determine whether oxcarbazepine does impact cognitive function. </p> <p>Separate from this, we had also specified that we would conduct multiple subgroup analyses to investigate any potential clinical or statistical heterogeneity. Given that only six studies were eligible for inclusion in the review originally, the splitting of data into subgroups may have led to some subgroups being underpowered. Some subgroups contained data from only one study, whilst other subgroups contained very low numbers of participants, despite including data from multiple studies. For this reason, caution is required when considering, or applying, any of the findings derived from the subgroup analyses performed in this review. </p> <section id="CD012433-sec-0094"> <h4 class="title">Certainty of the evidence</h4> <p>For this review, we assessed that three of the studies were at high risk of bias (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>); and the other three studies were at unclear risk of bias (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). Three studies failed to provide specific information regarding the method for randomisation and allocation concealment (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0004" title="KraiprabP , ChinvarunY , TantisiraMH . Oxcarbazepine as add‐on therapy in Thai epileptic patients with refractory partial seizures. Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]2005;88(Suppl 3):S193‐201. ">Kraiprab 2005</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). A further two studies did not describe how effective blinding was achieved and maintained (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). There were additional concerns regarding attrition bias. We rated two of the studies as being at high risk of attrition bias, as they both had attrition rates that well exceeded 20% of the randomised population (<a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>; <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>). By contrast, we deemed another two studies to be at unclear of risk of attrition bias because the attrition rate was below 20% of the randomised population, but was not balanced across the treatment groups (<a href="./references#CD012433-bbs2-0003" title="GlauserT A , NigroM , SachdeoR , PasterisL A , WeinsteinS , Abou‐KhalilB , et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology2000;54(12):2237‐44. GlauserT A , SachdeoR C , BebinM , WhelessJ W , D'SouzaJ . Two‐year long‐term safety and efficacy data of oxcarbazepine in children with refractory partial epilepsy [abstract]. Epilepsia2002;43(Suppl 7):57‐8. GlauserT A , SfikasN . Oxcarbazepine adjunctive therapy in children with inadequately controlled partial seizures: an analysis of seizure‐free rates. Epilepsia2003;44(Suppl 9):266. GlauserT , SachdeoR , BebinM , WhelessJ W . Two year long‐term safety and efficacy of oxcarbazepine (TrileptalÂ®) in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Differential efficacy of oxcarbazepine and carbamazepine during adjunctive therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 7):64. SachdeoR , GlauserT , WhelessJ , BebinM , BeydounA , D'SouzaJ . Oxcarbazepine (TrileptalÂ®) provides additional benefits over carbamazepine as combination therapy in children with refractory partial epilepsy. Epilepsia2002;43(Suppl 8):183. SachdeoR , GlauserT , WhelessJ , BebinM , D'SouzaJ . Oxcarbazepine adjunctive therapy in children is effective whether used with carbamazepine or other antiepileptic drugs. Annals of Neurology2002;52(3 Suppl 1):S119. WilfongA , ConstantineS , McCagueK , D'SouzaJ . Oxcarbazepine added to other sodium channel blockers or antiepileptic drugs improves seizure control in children with refractory seizures. Epilepsia2004;45(Suppl 7):146. ">Glauser 2000</a>; <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a>). </p> <p>The serious risk of bias, detected across the studies, led to us downgrading the certainty of evidence to moderate certainty for each of the outcomes included in the GRADE assessment. We rated the evidence as moderate certainty both for the incidence of treatment withdrawal and for the incidence of the adverse effects 'ataxia' and 'hyponatraemia', meaning that we are fairly certain that the conclusions made regarding these outcomes are accurate. Further concerns about the significant statistical heterogeneity detected across the data set for the efficacy outcomes 'responder rate' and 'seizure freedom' resulted in the certainty of evidence being downgraded again to low certainty for these two outcomes. Notably, seizure freedom was downgraded again due to imprecision, based on the sub‐optimal number of events constituting the analysis, but was upgraded back to low certainty because of the large effect size recognised. Similarly, the certainty of evidence for the adverse effects 'nausea' and 'somnolence' were further downgraded to very low and low, respectively, due to serious statistically significant heterogeneity and imprecision. </p> <p>For the outcomes for which the evidence was rated as either low or very low certainty, this means that we are less certain that the effect size calculated, and consequently the conclusions reached, are accurate about the true effect of oxcarbazepine. </p> </section> </section> <section id="CD012433-sec-0095"> <h3 class="title" id="CD012433-sec-0095">Potential biases in the review process</h3> <p>During the screening process, we recognised several studies that appeared to be eligible for inclusion in the review (<a href="./references#CD012433-bbs2-0020" title="CTRI/2010/091/000100 . A Clinical Trial to Investigate Efficacy and Safety of Eslicarbazepine Acetate Tablet versus Oxcarbazepine SR Tablet Eslicarbazepine as an Adjunctive Treatment in Patients With Refractory Epilepsy Suffering From Partial Onset Seizures With or Without Secondary Generalisation [A Multicenter, Randomized Open‐Label, Comparative, Prospective Clinical Trial to Investigate Efficacy and Safety of Eslicarbazepine Acetate Tablet versus Oxcarbazepine SR Tablet as an Adjunctive Treatment in Patients With Refractory Epilepsy Suffering From Partial Onset Seizures With or Without Secondary Generalisation]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1315 (first received 13 September 2010). ">CTRI/2010/091/000100</a>; <a href="./references#CD012433-bbs2-0021" title="CTRI/2010/091/001194 . Clinical Study to evaluate efficacy and safety of Eslicarbazepine acetate as an adjunctive therapy in partial‐onset seizures. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1992 (first received 9 August 2010). ">CTRI/2010/091/001194</a>; <a href="./references#CD012433-bbs2-0022" title="CTRI/2010/091/006085 . 13‐week study for evaluation of efficacy and safety of in‐aqul‐002 tablet compared to oxcarbazepine sustained‐release tablet as adjunctive treatment in adult patients with refractory partial‐onset seizures [An open label, randomized, parallel group, prospective, multicentre clinical trial for evaluation of efficacy and safety of IN‐AQUL‐002 in comparison with oxcarbazepine sustained‐release as adjunctive treatment in adult patients with refractory partial‐onset seizures]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=2479 (first received 22 December 2010). ">CTRI/2010/091/006085</a>). We were unable to obtain the data or methodological details for the trials, however, despite contacting the relevant authors and pharmaceutical companies. Consequently, we could not assess these studies for inclusion and they are therefore listed in the <a href="./references#CD012433-bbs1-0003" title="">Studies awaiting classification</a> section of the text. Additional data would have strengthened the review and improved the robustness of the subgroup analysis. Importantly, additional data could also potentially change the conclusions of the review and, therefore, the missing studies must be regarded as a weakness of this review. Future updates of this review should seek whether the results of these trials have yet been published. </p> <p>We similarly contacted the study authors and sponsoring pharmaceutical companies of the studies included in the review to request the associated trial protocols. Unfortunately, we were only supplied with the trial protocol for <a href="./references#CD012433-bbs2-0006" title="NCT00050934 . Pediatric Epilepsy Study [A multicenter, rater‐blind, randomized, age‐stratified, parallel‐group study comparing two doses of oxcarbazepine as adjunctive therapy in pediatric patients with inadequately‐controlled partial seizures]. clinicaltrials.gov/ct2/show/NCT00050934 (first received 01 January 2003). Pina‐GarzaJ E , EspinozaR , NordliD , BennettD A , SpiritoS , StitesT E , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology2005;65(9):1370‐5. ">Pina‐Garza 2005</a>. This was especially problematic for the <a href="./references#CD012433-bbs2-0005" title="NCT00975715 . Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures [A multicentre, randomized, double‐blind, placebo controlled, parallel‐group study in children with inadequately controlled partial onset seizures to investigate efficacy, safety and tolerability of TRI476 (Oxcarbazepine) as adjunctive therapy]. ClinicalTrials.gov/show/NCT00975715 (first received 11 September 2009). ">NCT00975715</a> trial, for which the results have not been formally published. This meant that we had limited information regarding the methodological design of the trial. We could have gained this information from the trial protocol, had it been provided. </p> <p>Another potential issue with this review was alluded to earlier. In this review, we assessed and analysed numerous outcomes. Conducting multiple statistical comparisons increases the risk of type I and type II statistical errors occurring. Additionally, multiple subgroup analyses were also performed which were all largely underpowered. It is therefore possible that some of the conclusions described could be inaccurate, despite displaying statistical significance, as a result of these type I and type II errors. In future revisions of this review, it would be advisable to limit the number of outcomes measured, and impose restrictions on when a subgroup analysis can be conducted, to improve the reliability of these statistical assessments. </p> </section> <section id="CD012433-sec-0096"> <h3 class="title" id="CD012433-sec-0096">Agreements and disagreements with other studies or reviews</h3> <p>Multiple other reviews have similarly reported that oxcarbazepine is efficacious at reducing seizure frequency in drug‐resistant epilepsy (<a href="./references#CD012433-bbs2-0039" title="KalisMM , HuffNA . Oxcarbazepine, an antiepileptic agent. Clinical Therapeutics2001;23(5):680‐700; discussion 645. ">Kalis 2001</a>; <a href="./references#CD012433-bbs2-0024" title="BangLM , GoaKL . Spotlight on oxcarbazepine in epilepsy. CNS Drugs2003;18(1):57‐61. ">Bang 2003</a>; <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a>). Specifically, the review by <a href="./references#CD012433-bbs2-0024" title="BangLM , GoaKL . Spotlight on oxcarbazepine in epilepsy. CNS Drugs2003;18(1):57‐61. ">Bang 2003</a> stated that 20% to 54% of trial participants experience a 50% of greater reduction in seizure frequency whilst receiving oxcarbazepine. Comparably in our review, across the six studies we analysed we found that 23% to 59% of participants experience 50% or greater seizure reduction when randomised to oxcarbazepine. Notably, however, the review by <a href="./references#CD012433-bbs2-0024" title="BangLM , GoaKL . Spotlight on oxcarbazepine in epilepsy. CNS Drugs2003;18(1):57‐61. ">Bang 2003</a> was a narrative summary of data which collected from four studies, including three non‐comparative studies, and was not a meta‐analysis. </p> <p>In contrast, the review by <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> did include a meta‐analysis of data extracted from four randomised controlled trials to investigate oxcarbazepine for drug‐resistant epilepsy. <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> similarly emphasised that significantly more participants achieved a 50% or greater reduction in seizure frequency when receiving oxcarbazepine compared to when receiving placebo. During the meta‐analysis, however, <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> detected an increase in the risk ratio for 50% or greater seizure reduction responder rate with increased dosages of oxcarbazepine (600 mg/d: RR 2.11, 95% CI 1.32 to 3.35; 1200 mg/d: RR 3.24, 95% CI 2.11 to 4.98; 2400 mg/d: RR 3.83; 95% CI 2.59 to 5.97). In our own subgroup analysis according to dosage, we observed that the risk ratio for 50% or greater seizure reduction remained around 2.00, regardless of oxcarbazepine dose; thus we were unable to replicate their finding in our current review. </p> <p>Importantly, in their review the calculated risk ratios only included data from one study which consisted of a purely adult study population: namely, the RCT by <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a>, which was also included in our current review. In our review, we have included data from up to three studies for each of the subgroups during the subgroup analysis, stratified by dose of experimental oxcarbazepine. Furthermore, with our review being more recently published, it contains more up‐to‐date evidence for the effect of oxcarbazepine. Specifically, our review contains the latest publication by <a href="./references#CD012433-bbs2-0002" title="EUCTR2008‐003333‐25‐BG . PROSPER [Multicenter, double‐blind, randomized, placebo‐controlled, three‐arm, parallel group study to evaluate the efficacy and safety of oxcarbazepine extended‐release (OXC XR) (1200 and 2400mg/day) as adjunctive therapy in subjects with refractory partial seizures due to epilepsy on up to three concomitant antiepileptic medications]. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐003333‐25/BG (first received 28 August 2009). FrenchJA , BaroldiP , BrittainST , JohnsonJK , Abou‐KhalilB , BrowerR . Efficacy and safety of extended‐release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial‐onset seizures: A randomized controlled trial.. Acta Neurologica Scandinavica2014; Vol. 129, issue 3:143‐53. HorichT , BrittainS , LouroD , JohnsonJ , BaroldiP . Efficacy and tolerability of spn‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Epilepsy Currents / American Epilepsy Society2012;12(Suppl 1):224, Abstract no: 2. JohnsonJ , BrittainS , LouroD . Efficacy and tolerability of SPN‐804, a novel, once‐daily, extended‐release formulation of oxcarbazepine: Adjunctive treatment of refractory partial seizures in a north american subpopulation. Neurology2013; Vol. 80, issue 7 Supplement:P02.213. NCT00772603 . Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1) [Phase III study to evaluate the efficacy and safety of OXC XR as adjunctive therapy in subjects With refractory partial seizures]. clinicaltrials.gov/ct2/show/NCT00772603 (first received 15 October 2008). ">French 2014</a>, which would not have been available at the time of publication for <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a>. As a result, our calculated risk ratios should provide a more robust and accurate estimation of the oxcarbazepine treatment effect as it incorporates more data from multiple sources. </p> <p>Similarly, the risk ratios for seizure freedom (1200 mg/d: RR 17.59, 95% CI 2.37 to 130.35; 2400 mg/d: RR 25.41, 95% CI 6.26 to 103.10), calculated by <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a>, were much greater than those reported here. Again, they mainly relied upon data extracted from <a href="./references#CD012433-bbs2-0001" title="BarcsG , WalkerEB , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Oxcarbazepine placebo‐controlled, dose‐ranging trial in refractory partial epilepsy. Epilepsia2000;41(12):1597‐607. D'SouzaJ , ConstantineS , WamilA , McCagueK . Improved seizure control when oxcarbazepine is added to sodium channel blockers or other antiepileptic drugs. Epilepsia2004;45(Suppl 7):307‐8. WalkerEB , HalaszP , ElgerCE , ScaramelliA , StefanH , SturmY , et al. Safety and efficacy of oxcarbazepine in refractory epilepsy. Epilepsia2000;41 Suppl Florence:97. ">Barcs 2000</a> with only the risk ratio calculated for the highest oxcarbazepine dose (2400 mg/d) including data from an additional smaller study. Notably, one of the RCTs included in the meta‐analysis by <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> utilised oxcarbazepine as a monotherapy rather than as an adjunctive therapy, which could further explain any observed differences in our reported findings. </p> <p>The review by <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> did, however, comment that the trials which were included in the meta‐analysis were of medium to poor methodological quality. <a href="./references#CD012433-bbs2-0051" title="SaconatoH , PradoGF , PugaME , AtallahAN . Oxcarbazepine for refractory epilepsy: systematic review of the literature. Sao Paulo Medical Journal2009;127(3):150‐9. ">Saconato 2009</a> likewise highlighted the lack of methodological details regarding random sequence generation and allocation concealment which led to their judgement. Similarly in this review, there was an issue with the quality and certainty of studies, such that we judged all of the included studies to be at either a high or unclear risk of bias, which is a partial reflection of methodological quality. </p> <p>In contrast to our review, many other reviews and long‐term extension studies report that oxcarbazepine is well tolerated (<a href="./references#CD012433-bbs2-0026" title="BeydounA , KutluayE , MihaescuM , MinecanD . Clinical experience with oxcarbazepine. Today's Therapeutic Trends2002;20(1):69‐85. ">Beydoun 2002</a>; <a href="./references#CD012433-bbs2-0057" title="WalkerEB , FerroniA , LopezCA , SfikasN , SturmY . Long‐term efficacy and safety of oxcarbazepine (Trileptal®) combination therapy in patients with refractory partial seizures. Epilepsia2002;43(Suppl 8):123. ">Walker 2002</a>; <a href="./references#CD012433-bbs2-0024" title="BangLM , GoaKL . Spotlight on oxcarbazepine in epilepsy. CNS Drugs2003;18(1):57‐61. ">Bang 2003</a>). Many reviews specifically emphasise the increased tolerability of oxcarbazepine compared to carbamazepine, the molecule from which oxcarbazepine is structurally derived (<a href="./references#CD012433-bbs2-0042" title="KrämerC . Oxcarbazepine (Trileptal®): A new antiepileptic drug for mono‐ and add‐on‐ therapy. Aktuelle Neurologie2000;27(2):59‐71. ">Krämer 2000</a>; <a href="./references#CD012433-bbs2-0023" title="ArroyoS . [Oxcarbazepine]. Neurologia2001;16(8):370‐5. ">Arroyo 2001</a>; <a href="./references#CD012433-bbs2-0039" title="KalisMM , HuffNA . Oxcarbazepine, an antiepileptic agent. Clinical Therapeutics2001;23(5):680‐700; discussion 645. ">Kalis 2001</a>; <a href="./references#CD012433-bbs2-0036" title="Horga de la ParteJF , HorgaA . Oxcarbazepine in the treatment of epilepsy. A review and update. Revista de Neurologia2006;42(2):95‐113. ">Horga de la Parte 2006</a>). This mainly appears to be due to the reduced potential for drug interactions, resulting from enzyme induction, noted with oxcarbazepine (<a href="./references#CD012433-bbs2-0039" title="KalisMM , HuffNA . Oxcarbazepine, an antiepileptic agent. Clinical Therapeutics2001;23(5):680‐700; discussion 645. ">Kalis 2001</a>). In this review, we have instead highlighted issues with the tolerability of oxcarbazepine, especially when participants are titrated to the higher doses. Notably, treatment withdrawal was less problematic and less prevalent in the lower oxcarbazepine dose subgroups. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012433-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram.OXC: Oxcarbazepine" data-id="CD012433-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> <p>OXC: Oxcarbazepine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012433-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012433-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="ORBIT Matrix for primary, secondary and harm (safety) outcomes to investigate reporting bias" data-id="CD012433-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>ORBIT Matrix for primary, secondary and harm (safety) outcomes to investigate reporting bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 1 50% or greater reduction in seizure frequency." data-id="CD012433-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 1 50% or greater reduction in seizure frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 2 Ataxia." data-id="CD012433-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 2 Ataxia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 3 Dizziness." data-id="CD012433-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 3 Dizziness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 4 Fatigue." data-id="CD012433-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 4 Fatigue.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 5 Nausea." data-id="CD012433-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 5 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 6 Somnolence." data-id="CD012433-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 6 Somnolence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 7 Headache." data-id="CD012433-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 7 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 8 Hyponatraemia." data-id="CD012433-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 8 Hyponatraemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 9 Vertigo." data-id="CD012433-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 9 Vertigo.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 10 Diplopia." data-id="CD012433-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 10 Diplopia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 11 Rash." data-id="CD012433-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 11 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 12 Tremor." data-id="CD012433-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 12 Tremor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 13 Pyrexia." data-id="CD012433-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 13 Pyrexia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 14 Abnormal gait." data-id="CD012433-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 14 Abnormal gait.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 15 Abdominal pain." data-id="CD012433-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 15 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 16 Nystagmus." data-id="CD012433-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 16 Nystagmus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 17 Viral infection." data-id="CD012433-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 17 Viral infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 18 Vomiting." data-id="CD012433-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 18 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 19 Abnormal vision." data-id="CD012433-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 19 Abnormal vision.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 20 Upper respiratory tract infection." data-id="CD012433-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 20 Upper respiratory tract infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 21 Seizure freedom." data-id="CD012433-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 21 Seizure freedom.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine vs. control, Outcome 22 Treatment withdrawal." data-id="CD012433-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine vs. control, Outcome 22 Treatment withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 1 50% or greater reduction in seizure frequency." data-id="CD012433-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 1 50% or greater reduction in seizure frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 2 Seizure freedom." data-id="CD012433-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 2 Seizure freedom. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 3 Treatment withdrawal." data-id="CD012433-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oxcarbazepine vs. control (Subgroup analysis ‐ Control group), Outcome 3 Treatment withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 1 50% or greater reduction in seizure frequency." data-id="CD012433-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 1 50% or greater reduction in seizure frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 2 Seizure freedom." data-id="CD012433-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 2 Seizure freedom. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 3 Treatment withdrawal." data-id="CD012433-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine vs. control (Subgroup analysis ‐ Age group), Outcome 3 Treatment withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 1 50% or greater reduction in seizure frequency." data-id="CD012433-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 1 50% or greater reduction in seizure frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 2 Seizure freedom." data-id="CD012433-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 2 Seizure freedom. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 3 Treatment withdrawal." data-id="CD012433-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment), Outcome 3 Treatment withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 1 50% or greater reduction in seizure frequency." data-id="CD012433-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 1 50% or greater reduction in seizure frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 2 Seizure freedom." data-id="CD012433-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 2 Seizure freedom. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012433-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/urn:x-wiley:14651858:media:CD012433:CD012433-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_t/tCD012433-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 3 Treatment withdrawal." data-id="CD012433-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose), Outcome 3 Treatment withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/media/CDSR/CD012433/image_n/nCD012433-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012433-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine compared to control for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxcarbazepine compared to control for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> drug‐resistant focal epilepsy<br/> <b>Setting:</b> outpatients (except for 1 study which was conducted in a hospital setting to allow EEG‐recording)<br/> <b>Intervention:</b> Oxcarbazepine (600 mg/d, 1200 mg/d, 2400 mg/d, 10 mg/kg/d, and 60 mg/kg/d)<br/> <b>Comparison:</b> control (placebo or alternative lower dose of oxcarbazepine) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI for efficacy outcomes and 99% CI for adverse effects)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Oxcarbazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median percentage seizure reduction per 28 days</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The values reported ranged from 7.6% to 28.7% seizure reduction with 2 of the 3 studies specifically reporting percentage reductions of less than 10%. The median percentage seizure reduction for participants randomised to experimental oxcarbazepine treatment ranged from 26% to 83.3%. Importantly, for each study that described this outcome, the median percentage seizure reduction reported was consistently higher in experimental oxcarbazepine treatment group than in the control group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1494</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxcarbazepine likely increases the median percentage seizure reduction per 28 days attained by participants. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>50% or greater reduction in seizure frequency</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.80</b><br/> (1.27 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the number of participants achieving a 50% or greater reduction in seizure frequency but we are uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/> (275 to 555) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ataxia</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.54</b><br/> (0.86 to 7.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1227</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases the incidence of ataxia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (43 to 380) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hyponatraemia</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>#</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.53</b><br/> (0.27 to 23.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases the incidence of hyponatraemia.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 558</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1035</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Somnolence</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.03</b><br/> (1.17 to 3.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the incidence of somnolence but we are uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000<br/> (140 to 425) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Seizure freedom</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.86</b><br/> (1.19 to 6.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1494</b><br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>LOW</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine may increase the incidence of seizure freedom amongst participants but we are uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/> (42 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal</b> </p> <p>Follow‐up: 9 days to 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.75</b><br/> (1.44 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>1593</b><br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oxcarbazepine likely increases treatment withdrawal.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>292 per 1000<br/> (240 to 355) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI for efficacy outcomes, including treatment withdrawal, and 99% CI for adverse effects). </p> <p><sup>#</sup> For the adverse event, <b>Hyponatraemia</b> , we have reported the <b>Number of events recorded per number of randomised participants</b> rather than the <b>Anticipated absolute effects</b> . Under the circumstances, this measure was considered more informative.<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Evidence downgraded once for risk of bias: 3 of the studies had unclear risk of bias and 3 studies had high risk of bias. This was largely due to studies not specifying their methods for randomisation and allocation concealment, as well as due to high attrition rates noted in some studies. </p> <p><sup>b</sup> Evidence downgraded once due to inconsistency: significant heterogeneity between studies detected. </p> <p><sup>c</sup>Evidence downgraded once due to imprecision: wide confidence intervals and sub‐optimal number of events included in analysis. </p> <p><sup>d</sup>Evidence upgraded once for large effect: large effect size (RR &gt; 2.00). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine compared to control for drug‐resistant focal epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/full#CD012433-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012433-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxcarbazepine vs. control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.27, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Ataxia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.86, 7.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.81, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.07, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.77, 4.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.17, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.94, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hyponatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.27, 23.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vertigo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.62 [1.32, 16.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Diplopia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [2.83, 10.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.38, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.77, 5.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Pyrexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.71, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Abnormal gait <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.53 [1.74, 17.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.42, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Nystagmus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [1.90, 10.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Viral infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.06, 79.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [1.20, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Abnormal vision <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.59, 13.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.29, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.19, 6.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.44, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxcarbazepine vs. control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012433-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Control group)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.69, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Alternate oxcarbazepine dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.99, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.14 [2.62, 14.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Alternate oxcarbazepine dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.93, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.46, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Alternate oxcarbazepine dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.51, 3.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Control group)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012433-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Age group)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.60, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.58, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.36, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [2.07, 5.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.19 [2.29, 11.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.13, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.36, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.32, 4.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Age group)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012433-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 8 weeks or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.20, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.20, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [2.06, 4.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 8 weeks or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.9 [0.96, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.05, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.26 [2.83, 145.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 8 weeks or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [1.19, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.26, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.29, 2.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Duration of treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012433-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 600 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.32, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 1200 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.50, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.85, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Seizure freedom <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.15 [0.61, 43.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.71 [1.62, 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 2400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.28 [4.16, 25.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Treatment withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.55, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.21, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 2400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.92, 2.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oxcarbazepine vs. control (Subgroup analysis ‐ Experimental dose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012433.pub2/references#CD012433-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012433.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012433-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012433-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012433-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012433-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012433-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012433-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012433-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012433-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012433\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012433\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012433\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012433\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012433\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6nHUP32m&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012433.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012433.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012433.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012433.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012433.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717718365"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012433.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717718369"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012433.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbec58ed7936b',t:'MTc0MDcxNzcxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 